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 Telomere length maintenance is critical for cells that divide many times.  
Disrupting telomere length equilibrium causes short telomere syndromes, characterized 
by stem cell failure causing age-related degenerative disease, or cancer, a disease 
characterized by unregulated cell growth.  Mammalian telomeres are bound by a six-
membered shelterin complex. Mutations in the gene encoding shelterin protein TIN2 
have been identified in patients with short telomere syndromes. Understanding the 
mechanism of disease these patients has been challenged by incomplete understanding of 
how TIN2 regulates telomere length in normal cells.   
Because TIN2 has two known isoforms, we asked whether the isoforms have 
different roles in the cell.  Using CRISPR/Cas9 genomic editing, we incorporated an 
epitope tag at the endogenous TIN2 gene and found a new isoform.  Using 3’RACE and 
PacBio SMRT-sequencing we identified this third isoform, TIN2M, that retains the last 
intron and is expressed across human cell types.  We found that all three TIN2 isoforms 
localize to telomeres, but have different effects on telomere length as measured by 
Southern blot.   
Then, we asked whether TIN2 could regulate telomere length through interactions 
with TPP1, which is part of the TPP1/POT1 telomerase processivity complex. We 
adapted a cell-based system to test TIN2’s effects on telomerase using a direct telomerase 
activity assay. Surprisingly, we found that TIN2 cooperates with TPP1/POT1 to stimulate 
telomerase processivity.  All three TIN2 isoforms were able to stimulate telomerase 
processivity above previously observed TPP1/POT1 stimulation.  TIN2 did not stimulate 
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telomerase in the absence of TPP1/POT1 or in the presence of TPP1 TEL-patch mutants 
that do not stimulate telomerase, suggesting TIN2 functions with TPP1/POT1. 
Preliminary data also suggests that the patient with TIN2 mutations do not stimulate 
telomerase.  
We conclude that TIN2 is part of a heterotrimeric shelterin subcomplex with 
TPP1/POT1, and that TIN2/TPP1/POT1 plays an important role in binding single-
stranded telomeric DNA and stimulating telomerase.  We discuss these findings in the 
context of recent advances in understanding the telomerase holoenzyme, including a 
possible mechanism for coupling telomerase with lagging strand DNA replication.  We 
propose that uncoupling these two activities causes telomere shortening independent of 
that observed in the absence of telomerase activity. 
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Chapter 1. Introduction 
1.1 Telomeres 
Telomeres are protective nucleoprotein structures at the ends of linear 
chromosomes.  They are named from the Greek words τελος (end) and μερος (part) 
(Muller 1938).  Telomeres were first described as the end parts of chromosomes that 
serve a protective function distinct from broken or otherwise non-natural DNA ends 
(Muller 1938; McClintock 1941).  They also serve to counteract sequence loss due to the 
end replication problem, which is the inability of the DNA replication machinery to fully 
replicate linear DNA all the way to the end (Watson 1972; Olovnikov 1973) 
Different organisms have evolved different methods for protecting and 
maintaining the linear ends of DNA ends.  Viruses with linear genomes use special 
secondary structures or end-terminal DNA binding proteins to achieve full replication of 
their genomic DNA.  Most eukaryotes, such as Tetrahymena, budding and fission yeast, 
and vertebrates, have repetitive G-rich telomeres that are maintained by a unique reverse 
transcriptase enzyme called telomerase (Blackburn 1990). Some insects, such as 
Drosophila, use transposons to maintain and elongate telomeres (Casacuberta 2017) 
Human telomeres consist of roughly 8 kilobases of double-stranded TTAGGG 
repeats, with a single-stranded 3’ overhang of approximately 100 nucleotides.  The 
telomere is bound by six telomere specific proteins, known collectively as shelterin: 
TRF1, TRF2, POT1, TIN2, TPP1, and Rap1 (Figure 1.1). Telomeric repeat-binding 
factor 1 (TRF1) and Telomeric repeat-binding factor 2 (TRF2) bind double-stranded 
telomeric DNA (Zhong et al. 1992; Bilaud et al. 1997; Bianchi et al. 1997; Broccoli et al. 




Telomerase levels are highly regulated, with expression restricted to about 100-
250 copies per cell (Xi & Cech 2014). Telomere proteins both positively and negatively 
regulate access of telomerase to the telomere and modulate its activity. Telomere 
elongation occurs in late S-phase, and telomerase recruitment and activity are regulated 
by many different post-translational modifications (Vogan & Collins 2015). Finally, 
telomerase shows a slight preference for adding to shorter telomeres over longer 
telomeres (Hemann et al. 2001; IJpma & Greider 2003).  
There are still many unanswered questions about what determines the telomere 
length equilibrium set point and how telomerase maintains telomeres within this telomere 
length distribution.  The need for telomere length regulation is underscored by the 
consequences of shifting the telomere length equilibrium (Figure 1.2B).  Telomere 
shortening leads to senescence, apoptosis, and short telomere diseases, while continuous 
telomere lengthening allows the growth of cancer cells.  
1.3 Telomere length and human health 
 Telomere length regulation sets a balance between unregulated cell growth and 
age related degenerative diseases (Stanley & Armanios 2015).  An increased 
understanding of the biology underlying inherited forms of telomere syndromes has 
advanced our understanding of telomerase and telomere length regulation.  Both cancer 
and short telomere syndromes can be traced back to changes in the telomere length 
equilibrium. 
 One hallmark of cancer is the ability of cells to divide indefinitely, also known as 
replicative immortality.  To achieve this, a cell must find a way to maintain its telomeres, 
and over 90% of human cancers do this by activating telomerase (N. W. Kim et al. 1994).  
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Also, certain genetic variants that lead to telomere elongation cause predisposition to 
familial melanoma and other cancers (Robles-Espinoza et al. 2014; Trigueros-Motos 
2014; Shi et al. 2014). 
 Short telomere syndromes are a clinically heterogeneous collection of diseases 
that share the common etiology of short telomeres.  The short telomeres in these patients 
cause defects in tissue renewal, leading to disease in a variety of different tissues.  These 
diseases include both common diseases of pulmonary fibrosis and liver fibrosis and rare 
diseases such as Dyskeratosis Congenita and Hoyeraal-Hreidarsson syndrome. While 
these diseases are often fatal due to bone marrow failure or pulmonary fibrosis, patients 
may also have abnormal skin pigmentation, premature hair graying, liver cirrhosis, 
gastrointestinal issues, and problems in other tissues. 
1.4 Mutations in many different genes cause short telomere syndromes 
 Mutations in thirteen different genes have been identified to cause short telomere 
disease.  The TERT and TR components of telomerase can be independently mutated in 
short telomere patients.  Mutations in other factors involved in the processing and 
stability of telomerase RNA have also been found, including Dyskerin, NHP2, NOP10, 
Gar1, and Naf1 (Mary Armanios & Blackburn 2012).  TCAB mutations also affect 
telomere length through disrupting telomerase trafficking from Cajal bodies.  Mutations 
in two shelterin proteins, TIN2 and TPP1, as well as telomere replication factors RTEL1 
and CST subunits, have also been identified in short telomere patients.  These mutations 
are generally autosomal dominant and exhibit Mendelian inheritance (Nelson & Bertuch 
2012).  Because both the mutation and the parental telomere lengths are inherited, the 
disease often shows genetic anticipation, where progressive telomere shortening increases 
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different mutations in TPP1 or POT1 are linked to long telomeres in certain familial 
cancer syndromes (Shi et al. 2014; Robles-Espinoza et al. 2014; Trigueros-Motos 2014; 
Aoude et al. 2015). The complexity of the genetics underscores TPP1 and POT1 as 
important regulators of telomere length in humans.  
1.5 Shelterin Regulation of Telomere Length 
The shelterin proteins serve several roles, including preventing telomeric DNA 
damage response, helping with telomere replication, and regulating telomerase access to 
the telomere. The roles of these proteins in telomere length regulation is accepted, but not 
much is known about the mechanism through which they regulate telomere length.  
1.5.1 TRF1, TRF2, and Rap1 
 
Double-stranded telomere binding proteins have roles in regulating telomere 
length maintenance. In humans, TRF1 and TRF2 specifically bind telomeric double-
stranded DNA (Zhong et al. 1992; Broccoli et al. 1997; Bianchi et al. 1999).  TRF1 and 
TRF2 each have a single Myb-like DNA binding domain, and they each form a 
homodimer that contacts DNA with the two adjacent subunits. Each TRF protein also has 
a homodimerization domain, TRFH, which serves as a docking site for TIN2 and other 
proteins that interact with TRF1 and TRF2 (Fairall et al. 2001; Chen et al. 2008). 
Interestingly, in Saccharomyces cerevisiae, ScRap1 is not a homolog of TRF1 or TRF2 
but contains two Myb domains and binds double-stranded telomeric DNA as a monomer.  
Rap1 is conserved in humans but has lost its DNA binding domains, instead interacting 
with telomeres through TRF2.  
TRF1 overexpression results in progressive telomere shortening, while 
overexpression of a dominant-negative TRF1 that cannot bind DNA causes telomere 
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elongation (van Steensel & de Lange 1997; Smogorzewska et al. 2000).  Similarly, TRF2 
overexpression causes telomere shortening over time, but neither TRF1 nor TRF2 appear 
to have a direct effect on telomerase activity (Smogorzewska et al. 2000).  
TRF2 deletion triggers an ATM- and p53-mediated DNA damage response and 
chromosome end fusions (Karlseder et al. 1999; Denchi & de Lange 2007), while TRF1 
deletion leads to an ATR-mediated DNA damage response (Sfeir et al. 2009).  These 
observations have led TRF1 and TRF2 to be described as repressors of ATM and ATR, 
respectively, but it should be noted that these two DNA damage signaling pathways may 
not be actively suppressed, but rather activated upon removal of these proteins.  Indeed, 
telomerase elongation in cells requires ATM kinase, so telomere elongation may depend 
on balancing signals from these different proteins (Lee et al. 2015; Tong et al. 2015). 
Rap1 function in human cells is poorly understood compared to its homolog in 
yeast.  While Rap1 overexpression causes telomere elongation (Li et al. 2000) and certain 
Rap1 deletion constructs alter telomere length heterogeneity in cells (Li & de Lange 
2003),  it does not appear to have an important role in mammalian telomeres.  Deletion of 
Rap1 does not cause any telomere dysfunction or telomere length effects, and it is 
thought to serve largely non-telomeric functions as a transcription factor in human cells 
(Kabir et al. 2014). 
1.5.2 TPP1 and POT1 
 
TPP1/POT1 form a heterodimer that functions as a telomerase processivity factor 
and is also important for telomere end protection in cells.  POT1 binds the telomeric 
single-stranded DNA (ssDNA) footprint TAGGGTTAG using its two N-terminal OB 
fold domains (Loayza et al. 2004) (Figure 1.4). Overexpression of POT1 does not lead to 
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function of TPP1/POT1 in cells (David Frescas & de Lange 2014a; Takai et al. 2011; 
Abreu et al. 2010; Frescas & De Lange 2014) (Figure 1.4). 
Short telomere patients have been identified with a TPP1 ΔK170 mutation that 
deletes one residue from the TEL-patch, deforming the TEN domain binding interface 
and disrupting the TPP1-telomerase interaction (Kocak et al. 2014; Bisht et al. 2016).  
This leads to decreased telomerase association with telomeres and decreased telomerase 
processivity. A POT1 S322L mutation in Coats Plus is thought to cause short telomeres 
through defective telomere replication, but the mechanism for this is unclear (Takai et al. 
2016). 
While the biochemical interactions of TPP1/POT1 with telomeric DNA and 
telomerase are fairly well understood in vitro, the in vivo regulation of telomerase has 
been challenging to study.  Most of the information about telomere length regulation in 
human cells has been studied by knock-down/knock-out or overexpression studies of 
different shelterin proteins followed by measurement of telomere length changes.  
Telomere binding proteins are ubiquitously expressed, but typically at low levels. 
Disrupting the protein levels may change telomere length by disrupting stoichiometry and 
protein localization, rather than identifying a true mechanism of telomere length 
regulation. For example, both TPP1 and POT1 were initially identified as negative 
regulators of telomere length through knock-down and overexpression studies, but 
TPP1/POT1 acts as a processivity factor in vitro. For further discussion, see Chapter 2. 
1.5.3 TIN2 
 
TIN2 is encoded by the TINF2 gene on chromosome 14. The TIN2 protein is 
required for TPP1/POT1 localization and telomere end-protection and has been described 
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as a molecular bridge between the dsDNA- and ssDNA- binding shelterin proteins.  TIN2 
is expressed as two isoforms, TIN2S and TIN2L, but most of the research on TIN2 has 
been performed in the shorter isoform TIN2S, which was described first.  TIN2L contains 
all 354 amino acids of the TIN2S sequence, with an additional 97 C-terminal amino 
acids,  and it has been described as being associated with the nuclear matrix (Kaminker et 
al. 2009) (Figure 1.5). 
TIN2S was initially discovered as a TRF1 interacting factor through a yeast two-
hybrid screen (Kim et al. 1999). An internal region of TIN2 contains the sequence 
FxLxP, a TRF1-interaction motif that binds directly with the TRF1 homodimerization 
(TRFH) domain (Chen et al. 2008).  It was later observed that TIN2 also interacts with 
TRF2 (Kim et al. 2004; Ye, Donigian, et al. 2004) and TPP1 (Ye, Hockemeyer, et al. 
2004; Houghtaling et al. 2004) (Figure 1.5).  TIN2 is required for assembly of shelterin 
and its localization to the telomere (O’Connor et al. 2006; Kim et al. 2008; Ye, Donigian, 
et al. 2004; Liu, O’Connor, et al. 2004). Removal of TIN2 by shRNA or Cre-mediated 
TIN2 deletion coincides with a loss of telomeric TRF1, TRF2, TPP1, and POT1 staining 
by immunofluoresence (Kim et al. 2004; Ye, Donigian, et al. 2004; Takai et al. 2011; 
David Frescas & de Lange 2014a). Disrupting shelterin localization then leads to a 
telomeric DNA damage response and cell death. TIN2 knock-out mice have been created, 
and while the heterozygous mice are viable, the TIN2 homozygous deletion is embryonic 
lethal (Chiang et al. 2004). Interestingly, no other information has been reported about 
the telomere length effects in the heterozygous mice.  
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at S295 and S333 by RSK2 has also been demonstrated, but the consequences of this 
modification are not clear (Yang & Counter 2013). 
TIN2 has been referred to as a negative regulator of telomere length based on 
results from knockdown and overexpression experiments. Overexpression of TIN2S in 
telomerase positive cells led to a slight repression of telomere elongation (Kim et al. 
1999; Yang et al. 2011). N-terminal truncation of the first 196 amino acids in the TIN2-
13 construct caused rapid telomere elongation (Kim et al. 1999; Yang et al. 2011).  This 
was interpreted as alleviation of TIN2 repression of telomere elongation. The TIN2 N-
terminus was later found to contain the TRF2- and TPP1-interaction domain (Kim et al. 
2004; Houghtaling et al. 2004).  Similarly, deletion of the TPP1 TIN2-binding domain 
abolishes TPP1 telomeric localization and causes telomere elongation in telomerase 
positive cells (Houghtaling et al. 2004; O’Connor et al. 2006).  These results also mimic 
the loss of POT1 telomeric localization (see previous section and Chapter 2.3). It is 
increasingly clear that TIN2 is required for TPP1/POT1 localization and function at 
telomeres (Takai et al. 2011; David Frescas & de Lange 2014a; Abreu et al. 2010). 
 Based on the classification of TIN2 as a negative regulator of telomere length, it 
was surprising to find TINF2 mutations that cause short telomere disease.  The patient 
mutations are mostly single base changes that result in missense or nonsense mutations in 
the protein, and they all cluster in a domain of unknown function in exon 6 (Savage et al. 
2008; Walne et al. 2008; Sasa et al. 2012).  Mutations in this cluster often cause rapid 
telomere shortening in one generation, which is striking compared to other short telomere 
disease mutations that cause gradual telomere shortening over multiple generations 
(Walne et al. 2008; M Armanios & Blackburn 2012) (Figure 1.3 &1.5).  
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Interestingly, the TIN2 patient mutations do not seem to disrupt interactions with  
its binding partners TRF1, TRF2, or TPP1 when tested by co-immunoprecipitation of 
overexpressed TIN2S and the respective binding partners (Yang et al. 2011; Xin & Ly 
2012).  Mutant TIN2S proteins also localize to the telomere (Yang et al. 2011). Because 
the patients are heterozygous for the disease causing mutations, the mutations are thought 
to function in a dominant negative manner.   
Several mechanisms have been proposed for telomere shortening with TIN2 
mutations, but the true mechanism is not clear. Co-immunoprecipitation of telomerase 
with the patient mutations in TIN2S brought down less telomerase activity measured by 
the telomeric repeat amplification protocol (TRAP) assay and less telomerase RNA 
measured quantitative real-time PCR (qRT-PCR), leading to the proposal that the TIN2 
mutants are defective at recruiting telomerase through TPP1 (Yang et al. 2011). Knock-in 
of the R282H mutation in human cell lines also decreased telomerase association with the 
telomere (Frank et al. 2015).  Others, however, have argued that there are also 
telomerase-independent mechanisms of telomere shortening. The HP1γ binding site is 
within the patient mutation cluster, and disrupting the TIN2S-HP1γ interaction leads to 
decreased sister telomere cohesion as measured by the distance between sister telomeres 
before mitosis (Canudas et al. 2011).  While it is not clear how sister telomere cohesion 
can cause a defect in telomere length maintenance, we conjecture that it may reflect an 
uncoupling of the leading and lagging strand replication machinery (see Chapter 4).  
Another experiment suggesting a role of fork collapse in telomere shortening is that 
knock-in of the corresponding K280E mutation in a telomerase RNA (TR) knock-out 
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mouse (K267E) is argued to cause more rapid telomere shortening than TR knock-out 
alone (D Frescas & de Lange 2014). 
While two studies of TIN2 mutations have been performed at the endogenous 
locus, most of the telomere length effects of normal and mutant TIN2 have only been 
studied in the TIN2S isoform using either overexpression or knockdown methods. 
Additionally, while there are many proposals about how TIN2 mutations may affect 
telomere length, the mechanism of telomere shortening in patients with TIN2 mutations 
remains unclear.  Here we set out to learn more about the two TIN2 isoforms and test 
whether they affect telomerase activity through the TIN2-TPP1 interaction.  We found 
that TIN2 is actually expressed as three isoforms that have different effects on telomere 
length in cells.  We also found that TIN2 stimulates telomerase processivity, implicating 
it as a player in the telomerase processivity complex.   In light of these results and other 
recent findings in the field, we discuss the implications of TIN2 as part of a single-
stranded binding complex that stimulates telomerase processivity and propose that TIN2 




Chapter 2. TIN2 has multiple expressed isoforms in human cells 
2.1 INTRODUCTION  
TIN2 was discovered in a yeast two-hybrid screen for TRF1-interacting factors.  
The 39kDa interacting protein had 354 amino acids encoded by a cDNA containing 
exons 1 through 6 of the TINF2 gene (Kim et al. 1999). Later analysis of the gene 
structure and comparison to the mouse TIN2 gene revealed conserved exons 7, 8, and 9 
in the TIN2S 3’UTR (Kim et al. 2003).  A second isoform was identified that splices 
together all 9 exons, encoding a 50 kDa protein with 451 amino acids (Figure 2.1A) 
(Kaminker et al. 2009). These two isoforms were renamed TIN2S and TIN2L. TIN2L 
contains the entire TIN2S sequence, with an additional 97 amino acids at the C-terminus. 
Both TIN2 isoforms are expressed in multiple different tissues and cell lines and contain 
the known interaction domains and the patient mutation cluster (Kim et al. 1999; 
Kaminker et al. 2009) (Figure 2.1). Mouse cells only express one TIN2 isoform that is 
414 amino acids long and more closely resembles TIN2L (Kaminker et al. 2009). 
 TIN2 is only found in vertebrates, and multiple sequence alignment of known or 
predicted TIN2 proteins shows several regions of strong sequence conservation (Figure 
2.1 B, Appendix B).  The N-terminus, which binds TRF2 and TPP1, is highly conserved.  
This region is predicted to be coiled-coil, and the pattern of conserved residues suggests a 
conserved helical interaction interface.  The TRF1 binding motif, FxLxP, and the patient 
mutation cluster are also both highly conserved (Figure 2.1) (Chen et al. 2008). 
Interestingly, the C-terminal region that is unique to TIN2L also contains a region of 
highly conserved residues that are present in mouse TIN2, but not TIN2S. Within this 
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conserved region is a patch of amino acids whose sequence identity is conserved across 
mammals. Because there is a conserved region in the long isoform that is missing from 
short isoform, we think there may be functional differences between the two isoforms. 
Previous work on TIN2 has mostly studied TIN2S, and therefore any unique 
functional contribution of TIN2L has not been observed in these experiments.  Initial 
TIN2S overexpression experiments in HT1080 cells, which maintain very short 
telomeres, showed TIN2S overexpression had no effect or slight shortening effects on 
telomere lengths. However mutants lacking the N-terminus, which includes the TRF2 and 
TPP1 interaction regions, exhibit telomere elongation in a telomerase-dependent manner 
(Kim et al. 1999).  Later shRNA knockdown experiments showed a modest increase in 
telomere length with reduced levels of TIN2 (Ye & de Lange 2004).  These results have 
led TIN2 to be described as a negative regulator of telomere length. While TIN2L has 
been described as nuclear matrix associated, its effects on telomere length have not been 
reported. 
 Because both TIN2 isoforms contain the patient mutation cluster, we sought to 
determine which is the predominant TIN2 isoform in human cells and to ask whether they 
contribute differently to telomere length regulation. To address the questions about the 
TIN2 isoforms in human cells, we tagged the endogenous locus using CRISPR/Cas9 
(Jinek et al. 2012; Jinek et al. 2013). In edited clones, we found evidence for three 





We wanted to address unanswered questions about the endogenous expression 
and functions of TIN2 isoforms in human cells. We were unable to identify a TIN2 
antibody that specifically recognized TIN2 protein at endogenous levels. Therefore, to 
study the expression differences in expression between TIN2S and TIN2L, we decided to 
tag the endogenous gene in cultured cells. 
2.2.1 CRISPR editing of the TINF2 gene 
 
 We chose to perform CRISPR/Cas9 editing in 293FT cells because of their robust 
transfection efficiency (>90%) and growth.  Using a guide RNA that targets Cas9 to 
make a cut just 3’ of the start codon (Figure 2.2A), we transfected a plasmid containing 
Cas9-2A-Puro and the guide RNA, as well as a homology-directed repair template (Ran 
et al. 2013).  Cells receiving Cas9 were enriched with a short puromycin selection and 
cloned by limiting dilution into 96-well plates. We screened the cells by PCR 
amplification of the locus and BglII digestion.  Positive clones had a 30 base-pair 
insertion and a BglII cut site, so digested fragments can be identified on a 2% agarose gel 
(Figure 2.2A and B).  
Of the 73 clones that grew and had interpretable PCR products, we found 77% 
had at least one edited allele, and 36% appeared to be homozygous for the insertion.  The 
293FT cell line, however, is hypotriploid with an unstable karyotype, making it 
challenging to assess true homozygosity. Also, we observed high endogenous Myc 
expression that interferes with western blotting for myc-tagged TIN2 (Figure 2.2 C, lane 
2).  These caveats make it difficult to study TIN2 in our knock-in cell lines, so future 
studies of endogenously edited TIN2 should repeat the targeting in a diploid cell line.  
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Western blots on several of the positive clones unexpectedly showed three distinct 
bands when probed with the myc antibody instead of the expected two bands (Figure 
2.2C). To independently test this finding, we cloned and myc tagged the full-length TIN2 
gene into an expression vector under the CMV promoter. In transfected cells 
overexpressing this construct, we again observed the three bands.  Using cDNA for 
TIN2S and TIN2L, we compared the size of the bands and determined that the 
unidentified band was an intermediate band that ran at approximately 47 kDa (Figure 2.2 
C, right).  Because the middle band is discrete and not a smear, we suspected was a new 
isoform rather than a post-translational modification.  
2.2.2 Identification of a new isoform, TIN2M 
 
Although TIN2 is known to be alternatively spliced, we could not predict the 
sequence of the new isoform.  To identify all spliced isoforms, we set out to sequence 
full-length TIN2 transcripts. To do this, we adapted 3’RACE (Frohman et al. 1988; 
Frohman 1993; Scotto–Lavino et al. 2007) combined with Pacific Biosciences (PacBio) 
Single-Molecule, Real-Time (SMRT) sequencing to sequence the transcript from the 
5’UTR through the polyA tail.  Sequencing full-length transcripts is feasible because the 
entire TIN2 gene is less than 4 kb, and PacBio sequencing is capable of generating long 
sequence reads (Pan et al. 2008; Carneiro et al. 2012; Steijger et al. 2013).   
First, we reverse transcribed mRNA from several different cell lines with an 
oligo-dT20 primer with an adapter sequence, then PCR amplified the cDNA using primers 
targeting the adapter sequence and the 5’-UTR (Figure 2.3A). This PCR amplification did 
not produce discrete bands on agarose gels, but TOPO cloning and sequencing indicated 
that most inserts were specific TIN2 amplicons. 
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To sequence full-length PCR products with PacBio SMRT-sequencing, we 
prepared libraries from the 1-3kb fraction of the PCR products after size selection. 
Sequencing reads were processed in the SMRT Analysis v4.0 software, which generates 
circular consensus sequence (CCS) reads. Full-length reads were identified based on the 
presence of the polyA and primer sequences. The program then clusters the reads to 
generate high-quality sequences (Gordon et al. 2015).  These reads were aligned to the 
genome using HISAT2 and assembled into potential transcripts using StringTie (Figure 
2.3A) (Pertea et al. 2015; Kim et al. 2015; Pertea et al. 2016). 
When we amplified and sequenced endogenous TIN2 transcripts from 293T cells, 
we found that TIN2S and TIN2L are expressed along with a third major isoform, 
“TIN2M”. TIN2M results from retention of the last intron, between exons 8 and 9, 
resulting in some unique sequence coded from the intron before reaching a stop codon 
(Figure 2.3B). FPKM values output by StringTie indicate that TIN2M and TIN2L 
transcripts are expressed at the same levels, and TIN2S is about 10-fold higher. The 
relative abundance can also be visualized by looking at the coverage across TINF2 
(Figure 2.3C). About one-third of the reads contain the retained intron between exons 6 
and 7, which is present in TIN2S only.  Roughly two-thirds of the reads contain the 
retained intron between exons 8 and 9, which is present in both TIN2S and TIN2M, but 
not TIN2L.  This suggests that the isoforms are expressed at similar levels. However, 
because of the PCR amplification step, these results are not quantitative and represent a 




To determine whether TIN2M is expressed in other cell types, we sequenced 
RNA from four other human cell lines (HeLa, K562, RPE-1, and an LCL) and two cell 
lines from different mouse strains, C57BL/6 and CAST/EiJ. TIN2M was present as a 
major isoform in all of the human cell lines in similar ratios to what we had seen in the 
293T cells. Mouse TIN2 was only expressed as one isoform in both strains, as previously 
described (Kim et al. 2003; Kaminker et al. 2009) (Appendix C). 
When we looked at the processed, aligned reads, we noticed many recurrent and 
unique minor TIN2 splice variants in the human cell lines in addition to the three major 
isoforms. These variants include skipping of exon 2 (Ishdorj et al. 2017), skipping exons 
4 and 5, skipping exons 2-5, or retention of the first intron (Figure2.3D).  In addition, 
alternative polyadenylation was also observed on all three isoforms. These abnormal 
splicing events were observed specifically in human and not the mouse cell lines. 
Publicly available data from PacBio IsoSeq, which is a whole genome RNA-seq 
method using PacBio sequencing technology with no PCR amplification step, show 
expression of TIN2M and other variants in mcf-7 breast cancer cells (Pacific Biosciences 
2015). Genome-wide ribosome profiling data from GWIPS-viz also suggest that TIN2M 
may be translated in human cells, as ribosome peaks are present in the unique coding 
region of the retained intron between exons 7 and 8 (Michel et al. 2014).  
Having discovered a new TIN2 isoform, we wanted to determine its effects at the 
telomere.  All three isoforms share exons 1-6, which contain the known interaction 
domains, binding motifs, and the patient mutation cluster, but differ in their C-terminal 
domains.  To determine whether they have different effects in human cells, we 
overexpressed cDNA encoding TIN2S, TIN2M, or TIN2L with or without the K280E 
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patient mutation in HeLa cells and looked at the localization and telomere length effects 
in these cells. 
2.2.3 TIN2 isoforms localize to the telomere 
 
To test whether the three isoforms of TIN2 localize to the telomere, we performed 
immunofluorescence on fixed cells.  We generated cell lines stably overexpressing N-
terminally myc-tagged TIN2S, TIN2M, or TIN2L under the CMV promoter in HeLa cells 
using the Invitrogen FLP-in system. Briefly, FLP-in cell lines have an FRT site at a 
single genomic locus along with a promoter and start codon for the selectable marker.  
The pcDNA5/FRT expression vector contains a selectable Hygromycin marker lacking a 
promoter and ATG start codon, so cells only express Hygromycin resistance if the 
plasmid integrated at the FRT locus. By using this system, we can ensure that each cell 
has one copy of the TIN2 expression construct. 
 Since shelterin is constitutively localized to telomeres, telomeres can be 
visualized by TRF2 immunofluorescence. We used myc antibodies to determine the 
localization of the TIN2 isoforms in these cell lines. Immunofluoresence showed punctate 
TRF2 staining, marking the telomeres.  Myc antibodies marking TIN2 showed a similar 
staining pattern with foci that co-localize with TRF2. This pattern was seen for in all 
three isoforms, indicating that the TIN2 isoforms all localize to the telomere (Figure 2.4).  
When we tested localization of TIN2S-K280E, TIN2M-K280E, or TIN2L-K280E, we 
found that they were also localized to telomeres.  This is consistent with previously 
reported data on TIN2S mutants (Yang et al. 2011).  Previous work to understand the 
defects in TIN2 mutants showed that the localization and protein-protein interactions of 




2.2.4 TIN2 isoforms have different effects on telomere length 
 
The HeLa-TIN2 cell lines were passaged to monitor telomere length changes over 
time.  TIN2S overexpression has been suggested to shorten telomeres (Kim et al. 1999; 
Yang et al. 2011), but the effect of TIN2L has not been reported.  We passaged HeLa-
TIN2 and HeLa-GFP control cells for eight weeks. We found that GFP and TIN2S 
overexpressing cell lines did not have significant changes in telomere length.  In contrast, 
TIN2M and TIN2L overexpressing lines had increased telomere length (Figure 2.5). 
We also examined the effects of the K280E patient mutation on telomere length in 
all three isoforms.  Previous work in TIN2S showed that overexpression of TIN2S-
K280E, TIN2S-R282S, or TIN2S-R282H (Yang et al. 2011) decreases telomere length 
more than overexpressing wild-type TIN2S.  Endogenous knock-in of the TIN2-R282H 
mutation in human cells showed a decrease in telomere length, although the degree of 
shortening varied between clonal cell lines (Frank et al. 2015). 
In our hands, TIN2S-K280E and GFP cell lines did not have significant telomere 
length changes.  These cells have very short telomeres, so it may be that they are already 
on the shorter end of tolerated telomere lengths. TIN2M-K280E and TIN2L-K280E, 
however, had a surprising increase in telomere length over time. This telomere elongation 
with TIN2 has only before been observed with overexpression of TIN2-13 construct 
(Kim et al. 1999), which lacks the amino acids 1-196 in TIN2S, consisting of the 
TPP1/TRF2 binding domains. 
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 In these experiments, we used genomic editing to identify a new TIN2 isoform, 
TIN2M, in addition to the known TIN2S and TIN2L isoforms.  We were able to sequence 
full-length TIN2 transcripts to identify that TIN2M results from a retained intron and 
contains all of the coding sequence of TIN2S, some of the TIN2L C-terminal sequence, 
and a short stretch of unique amino acids coded from the retained intron.  All three 
isoforms localize to the telomere, and the K280E patient mutation does not disrupt 
telomeric localization.  We found that, in contrast to TIN2S overexpression, TIN2M and 
TIN2L overexpression caused telomere elongation regardless of whether the patient 
mutation is present.  We think this is evidence that the TIN2 isoforms have different 
functions in the cell that are not yet known. 
 
2.3 DISCUSSION 
In our analysis of TIN2, we found that human cell lines express three major TIN2 
isoforms that localize to the telomere but have different effects on telomere length.  Our 
surprising results showing three isoforms suggest that, while we have many robust tools 
to study gene expression and function, unbiased approaches may reveal unexpected 
information about a gene of interest.  The N-terminal tagging of the full-length TINF2 
gene revealed an unknown expressed isoform that would not have been observed by 
studying the isoforms described and annotated in the literature.  
2.3.1 Genomic editing and long-read sequencing identify unpredicted splicing 
events 
 
The ability to analyze full-length reads of TIN2 cDNAs using PacBio SMRT-
sequencing identified transcript variants that would be missed in short-read sequencing 
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platforms. The long-read sequencing allowed us to identify a new isoform that does not 
have a novel splice junction, but rather a unique combination of splicing and intron 
retention. PacBio read lengths allow sequencing of the entire TIN2 transcript, and can be 
used to sequence much longer transcripts as well. In addition to identifying events of 
exon skipping, intron retention, and alternative polyadenylation, we can resolve which 
splicing events are happening in the same transcript. A recent study discovered an 
unusual TIN2 splice variant in chronic lymphocytic leukemia (CLL) cells (Ishdorj et al. 
2017).  This variant skips exon 2 in the context of TIN2S, however their methodology 
does not definitively show this event is exclusively in TIN2S transcripts, and it may be 
present in other isoforms.  We observed rare occurrences of this variation. While some 
were in TIN2S transcripts, others were in transcripts truncated by early alternative 
polyadenylation or with varying downstream splicing events not seen in TIN2S.  
PacBio SMRT sequencing is not often used due to its high frequency of insertions 
and deletions, but it is a valuable method for identifying isoforms with specific sequence 
structure, where the arrangement of exons is more relevant than nucleotide variation.  As 
long-read sequencing technologies improve, they should become the default choice for 
examining expressed mRNA sequences. 
Having identified three TIN2 isoforms, we still need to investigate what TIN2 is 
doing at the telomere to regulate telomere length.  In vivo or cell culture studies are also 
needed to determine the roles of each isoform in the cell.  Previous work on TIN2 has 
used methods such as shRNA knock-down that perturb protein levels or cDNA 
overexpression that biases isoform expression as well as perturbing protein levels. 
Because the stoichiometry of telomere proteins is tightly regulated, new approaches 
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should take advantage of advances in genome editing technologies. The field has been 
moving in this direction by generating a TIN2 mutant knock-in mouse and by using 
editing technologies to knock-in patient mutations in human cell lines (D Frescas & de 
Lange 2014; Frank et al. 2015), but more mechanistic studies are required to fully 
understand TIN2 function. 
2.3.2 Challenges in inferring telomere protein function 
 
One major drawback to the way telomere binding proteins have been studied is 
that the use of knock-down, knock-out, or overexpression experiments disrupt the 
delicate stoichiometry of telomere binding proteins, which is crucial to their functions. 
Most proteins have been defined as either positive or negative regulators of telomere 
length based on telomere length changes observed using these methods.  These changes, 
however, are more likely to be results of disruption of stoichiometry, which can titrate 
important factors away from the telomere, rather than of direct functions of the protein. 
TPP1 and POT1, for example, were initially thought to be negative regulators of 
telomere length.  POT1 overexpression does not lead to major telomere length changes, 
but expression of POT1ΔOB1 elongates telomeres due to failure to bind telomeric 
ssDNA (Loayza & de Lange 2003).  Overexpression of TPP1 leads to telomere 
shortening in HTC75 cells, but overexpressing TPP1 that cannot interact with TIN2 
elongates telomeres (Houghtaling et al. 2004).  Additionally, shRNA knock-down of 
TPP1 or POT1 leads to significant telomere elongation (Ye, Hockemeyer, et al. 2004; 
Veldman et al. 2004), and disrupting the POT1/TPP1 interaction mimics the telomere 
elongation of a POT1 knockout (Liu, Safari, et al. 2004).  
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These in vivo observations, however, are challenging to reconcile because the 
biochemical function of TPP1/POT1 suggest it is a positive regulator of telomere length. 
The TPP1/POT1 heterodimer serves as a telomerase processivity factor that binds 
telomerase and is required for telomerase localization to telomeres (Xin et al. 2007; 
Wang et al. 2007; Zhang et al. 2013; Zhong et al. 2012; Nandakumar et al. 2012).  
Disrupting the stoichiometry or localization of these complexes in cells could cause 
telomere length changes that are independent of the proteins’ normal functions. 
Overexpression TIN2, TPP1, or POT1 could sequester necessary components in 
non-telomeric locations, while knockdown of one component could cause a 
nonfunctional or partially functional complex.  Similarly, TIN2M or TIN2L 
overexpression could sequester functional TPP1/POT1 complexes away from their 
telomeric location, causing a telomere elongation phenotype similar to what is observed 
in POT1 knockouts.  Indeed, many telomere proteins, including TPP1 (Bisht et al. 2016) 
and telomerase (Armanios et al. 2005), exhibit haploinsufficiency, suggesting the 
stoichiometry is important for telomere length maintenance. 
Future experiments to study the TIN2 isoforms should employ endogenous 
genome editing with CRISPR/Cas9 to preserve the stoichiometry.  One question is 
whether each isoform of TIN2 is sufficient for cell survival, which can be addressed by 
forcing expression of one isoform and monitoring cell growth and telomere length.  It 
would be easy to force expression of TIN2S or TIN2M by mutating downstream splice 
sites, but forcing TIN2L expression may be more challenging.  Recombination-mediated 
cassette exchange (RMCE) (Toledo et al. 2006) may be a way to flank the endogenous 
gene with LoxP sites and concurrently remove endogenous TIN2 to force expression of a 
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downstream TIN2 isoform cDNA using the endogenous TIN2 promoter. We have 
designed an approach for this (Appendix F). 
While there are still many questions about the different TIN2 isoforms expressed 
in human cells, our experiments underscore the functional importance of the TIN2 patient 
mutation cluster and the C-terminus of TIN2.  Telomeric localization of the three 
isoforms containing a patient mutation further supports the dominant roles of the TIN2 
mutants.  The telomere length difference between the isoforms also suggests that the 
different TIN2 isoforms may have distinct roles in telomere length regulation, but the 
mechanism remains unclear
 
2.4 MATERIALS AND METHODS 
2.4.1 Multiple Sequence Alignments 
 
TIN2 sequences from vertebrates with known or predicted TIN2 proteins were obtained 
from NCBI.  The longer isoform was chosen for organisms with multiple reported 
isoforms. A list of organisms and accession numbers is reported in Appendix B. 
Sequences were uploaded to PRALINE multiple sequence alignment using the default 
parameters (Simossis & Heringa 2003; Simossis & Heringa 2005). To make the sequence 
conservation heat map, PRALINE output was imported into Microsoft Excel, and the 
alignment scores (0-10) of human TIN2 were colored from white=0, not conserved to 




2.4.2 Generation of TIN2 constructs 
 
TIN2 Expression Constructs  
TIN2S cDNA was purchased as an Invitrogen Ultimate ORF clone (IOH80607), in the 
pENTR221 Gateway Entry vector.  The stop codon was mutated to serine using site-
directed mutagenesis for downstream expression of a C-terminal epitope tag.  TIN2L was 
generated from the TIN2S entry clone by Gibson assembly with a synthetic gBlock Gene 
Fragments from Integrated DNA Technologies (IDT). The TIN2L gBlock contained the 
downstream TIN2 sequence with silent mutations for shRNA resistance (lowercase) and 








TIN2M was amplified from RT-PCR products that were cloned into PCR-II by TOPO 
cloning.  Linearized TIN2 entry vectors were cloned into Gateway Destination vectors 
pLenti6/UbC/V5-DEST (ThermoFisher V49910) or pcDNA-DEST40 (ThermoFisher 
11274015) using Gateway LR Clonase II (Invitrogen, 11791-020). 
TINF2, the TIN2 full-length gene inclusive of introns, was cloned into 
pcDNA5/FRT (ThermoFisher V601020) by amplifying the locus from a BAC (RPCI.11c 
clone number 368G9) and an N-terminal myc tag was incorporated just after the ATG 
start codon (Alder et al. 2015).  TIN2 isoform cDNAs were also cloned into 
pcDNA5/FRT by PCR amplification with primers containing HindIII and NotI restriction 
sites, an N-terminal myc tag, and a stop codon, followed by restriction cloning into the 
pcDNA5/FRT backbone.   
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All constructs and mutants were sequence verified by Sanger sequencing (Sanger 
& Coulson 1975) at the JHU Synthesis & Sequencing Facility. 
 
Site Directed Mutagenesis 
Site-Directed Mutagenesis (SDM) (Kirsch & Joly 1998; Sarkar & Sommer 1990) was 
used to generate patient mutations in the TIN2 vectors, and to mutate the TAG stop 
codon to TCG serine for C-terminal tag expression.  Primers were designed with 10-15 
bases on either side of the mismatch, a Tm ≥ 78°C, about 40% GC content, and 
beginning and ending in G or C where possible. The primers used were A4/A5 (mutating 
stop codon, see TIN2 Constructs), A6/A7 (K280E), A8/A9 (R282S), and A10/A11 
(R282H) (Appendix A). 
SDM PCR was performed with Pfu Turbo Polymerase (Agilent, 600252) using 14 
cycles of PCR with 55°C annealing temperature and 72°C extension.  PCR products were 
digested with DpnI (NEB, R0176L) for one hour at 37°C and transformed into 
subcloning efficiency DH5α (LifeTech, 18265017) and plated on 30μg/ml kanamycin for 
pENTR221 or 100 μg/ml carbenicillin (US Biological, C1100) for pcDNA5 backbones.  
Mutations were confirmed and the TIN2 coding sequence was checked for suprious 
mutations by Sanger sequencing. 
 
Overlap Extension PCR 
TIN2 truncation mutation K280X was generated by amplifying the pENTR221-
TIN2S plasmid with primers A14 and A19, and A17 and A20 (Appendix A). A19 and 
A20 each contain a 9nt complimentary overhang.  Products were gel purified and 10ng 
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each were used as template in a secondary PCR reaction with primers A14 and A17.  The 
full-length amplicon was then used directly in the Gateway LR reaction to clone into the 
expression vector.  
 
2.4.3 Cell culture methods 
 
Cell lines were cultured in the indicated media supplemented with 10% heat-inactivated 
FBS (Invitrogen, 10082147) and 1% penicillin/streptomycin/glutamine (PSG, Invitrogen 
10378-016) unless otherwise stated.  HeLa, 293T, 293FT, and 293TREx FLP-in cells 
were cultured in DMEM (Gibco), hTERT-RPE1 cells were cultured in DMEM/F12 
(Corning), patient-derived lymphoblastoid cell lines (LCLs) were cultured in RPMI 
(Gibco), and K562 cell lines were cultured in IMDM (Gibco). 
 
Generating Stable Cell Lines with the FLP-in system 
293 TREx FLP-in (Invitrogen, R78007) or HeLa TREx FLP-in cell lines (Invitrogen, 
R71407) were kind gifts from the Holland and Armanios labs.  To constitutively 
overexpress TIN2 isoforms, the respective TIN2 cDNA in the pcDNA5/FRT vector for 
expression under the CMV promoter was flipped into HeLa TREx cells.  A control cell 
line was generated with pcDNA5/FRT-EGFP. To generate these cell lines, on Day 0, 
2x105 cells were plated into 3 wells per construct in 6-well dishes. On Day 1, 900 ng 
pOG44 Flp-Recombinase (Invitrogen V600520) and 100 ng of the pcDNA5/FRT 
construct were transfected into each well using Lipofectamine 2000 (Invitrogen, 
11668019).  A set of negative control wells was included with pOG44 only, but no 
pcDNA5/FRT plasmid.  Once the wells were confluent (Day 2 or Day 3), the wells 
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containing the same construct were pooled and transferred to a 15cm dish and allowed to 
adhere to the plate.  The next day, hygromycin B (Roche, 10843555001) was added to a 
final concentration of 200μg/ml in DMEM.  Cells were maintained under selection for 
two weeks, changing the media with fresh antibiotic every 3 days, until all pOG44 only 
cells have died and colonies of hygromycin resistant cells were apparent on the FLP-in 
plates.   
 
2.4.4 CRISPR targeting of the endogenous TINF2 gene 
 
Constructs and Cloning 
Guide RNAs were selected using the Zhang Lab CRISPR design tool 
(http://crispr.mit.edu/).  For endogenous tagging of TIN2, the guide selected was 
cgccaccaggggcgtagccaTGG, which cuts just 3’ of the ATG start codon. The guide oligos 
were ordered with BbsI overhangs for subsequent cloning.  Oligos were phosphorylated 
and annealed by combining 1μl of each oligo with 10X T4 ligation buffer, T4 ligase 
(NEB M0202L), and water in a 10 μl reaction, and incubated at 37°C x 30 min, 95°C x 
5min, ramp down 5°C/minute to 25°C. 3μg of the backbone, pX459-U6- Chimeric_BB-
CBh-hSpCas9-2A-Puro (Ran et al. 2013) was digested with BbsI (NEB, R0539S) at 37°C 
for an hour, then run on a 1% agarose gel and extracted.  A 1:200 dilution of the annealed 
primers was ligated to the digested backbone. 
 
The donor template for the N-terminal myc tag was generated by PCR from the cloned 
TINF2 genomic locus with an incorporated myc tag.  To generate the linear donor DNA, 
the mycTINF2 construct was amplified with Phusion DNA polymerase (NEB, M0530L) 
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using two primers (A111, A112) that generate 250bp homology arms on either side of the 
myc tag.  Products were column purified and concentration was determined with the 
Nanodrop. 
 
CRISPR/Cas9 Editing in 293T cells 
To edit 293T cells, 4x105 cells were played on D0. On D1, 1μg of Cas9-2A-Puro+TIN2 
guide was transfected with 10 molar equivalents of the repair template using 
XtremeGENE9 (Roche, 6365787001) according to the manufacturer’s protocol.  As a 
transfection control, FUGW was transfected and checked for GFP fluorescence on the 
inverted fluorescent microscope, which allowed estimation of 80% transfection 
efficiency.  On D2, cells were split 1:3 and 3μg/ml puromycin was added.  After 48-72 
hours, most control cells and many of the Cas9 transfected cells died.  The surviving 
edited cells were trypsinized and plated for limiting dilution cloning. 
 
Screening Clones for editing events 
To screen the edited cells, one 96-well plate was expanded to two 48-well plates.  When 
confluent, the cells were disrupted and half were passaged into a fresh 96-well plate and 
half were harvested for a genomic DNA prep. For gDNA isolation, cells were tripsinized 
and transferred to a 96-well round bottom plate, washed with PBS, and resuspended in 
50μl Bradley lysis buffer (10mM Tris-HCl pH7.5, 10 mM EDTA, 0.5% SDS, 5M NaCl, 
1mg/ml Proteinase K) and incubated overnight in a humidified 55°C chamber.  DNA was 
precipitated with 100μl ice-cold ethanol/NaCl (100%/5M) for 30 minutes at room 
temperature, and then spun at 3000rpm for 20 minutes.  DNA pellets were washed with 
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ice-cold 70% ethanol, dried, and resuspended in 30μl warm TE pH 8.0. TE volume was 
later brought up to 50 μl because of the high viscosity. 
PCR screening was done on 1μl of genomic DNA in 96-well plate format with 
primers A109 and A110 (Appendix A) and TaKaRa Ex Taq polymerase (Clontech, 
RR001A) according to manufacturer instructions, with 35 cycles and annealing 
temperature of 65.2°C. Clones yielded a 284 bp band with BglII cut site.  To identify 
proper editing, BglII was diluted in NEB3 buffer and added to 10μl PCR products and 
incubated at 37°C for 1 hr. Only partial BglII digestion was achieved in PCR buffer, and 
positive and negative clones could be discerned by the shift in PCR band and presence of 
BglII digestion products. Presence of myc-TIN2 was subsequently tested by western 
blotting on select clones. 
 
2.4.5 Western Blotting 
 
Expression of myc-TIN2 CRISPR clones was assayed by western blotting.  Lysates were 
generated by harvesting one well of a 6-well plate in 100μl RIPA buffer (Sigma, R0278-
50ML), lysing on ice for 30 minutes with vortexing, and clearing the lysates by 
centrifugation at 4°C for 10 minutes at 8000rpm. Samples were denatured with 30 μl 4X 
LDS (Invitrogen, NP0008) with 50 mM DTT and heated at 65°C for 10 minutes. 
Proteins were separated by reducing SDS-PAGE electrophoresis on a 4-12% Bis-Tris gel 
(NuPAGE, NP0323) in 1X MOPS buffer (Invitrogen, NP0001) and transferred to PVDF 
(Immobilon FL, IPFL00010) in 1X NuPAGE Transfer Buffer (Invitrogen, 00061) with 
10% Methanol.  3 μl of the SeeBlue Plus2 (Thermo, LC5925) prestained ladder are 
included to estimate molecular weight. Membranes are then blocked in 1X TBS + 0.1% 
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Tween20 (TBST), 5% milk (Bio-Rad 170-6404) for 30 minutes at RT or overnight at 
4°C.  Primary antibody was diluted in blocking buffer and incubated with agitation at 
room temperature for 30 minutes to 2 hours. Primary antibodies and concentrations are as 
follows: mouse anti-myc 4A6 (Millipore 05-24), 1:2000; rabbit anti tubulin (Abcam, 
ab6046), 1:5000; mouse anti-V5 (Invitrogen R96025), 1:5000.  Blots were washed 3 
times with TBST and incubated with the appropriate secondary, anti-rabbit HRP or anti-
mouse HRP (Cell Signaling), diluted 1:10,000 in TBST. After 3 washes with TBST, blots 
are developed with SuperSignal West chemiluminescence substrate (Thermo, PI34095) 
and imaged on an ImageQuant LAS4000 imager. 
 
2.4.6 Determination of TIN2M isoform 
 
To determine whether the unidentified myc-TIN2 band is a previously unknown spliced 
variant, we performed a modified 3’RACE protocol where we amplified TINF2 
transcripts from the 5’UTR through the polyA sequence. PacBio sequencing allowed 
generation of full-length reads across the transcripts.  The 3’RACE and sequencing was 
performed using samples from five human cell lines (293T, HeLa, RPE-1, K562, LCL) 
and two mouse samples (CAST/EiJ MEFs, C57BL/6 liver). 
 
Isolation of RNA 
RNA was isolated from ≥106 cells using the RNeasy Kit (Qiagen, 74104).  Cells were 
washed with PBS and disrupted in RLT using QIAshredder spin columns (Qiagen, 
79654).  The RNA isolation follows the manufacturer protocol with an on-column DNase 
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digestion using the RNase-free DNase kit (Qiagen, 79254) to remove any genomic DNA, 
followed by RNA clean-up.  Concentration was estimated by NanoDrop.  
 
Modified 3’RACE 
3’RACE was performed as described in Molecular Cloning: A Laboratory Manual 
(Fourth Edition, CSHL Press, 2012) with modifications. To sequence full-length TIN2 
transcripts, 1.5ug RNA was reverse transcribed with the primer A124, an oligo-dT20-
Adapter primer, using the SuperScript III First Strand Synthesis Kit (Qiagen, 18080-051). 
5 μl of the resulting cDNA was amplified with Hot Start Phusion Polymerase (Thermo, 
F-549L) primers to the 5’UTR (Human-A111, Mouse: A142, Appendix A) and to the 
adapter (A123), using the annealing temperature of 46°C and a hot-start protocol to 
promote specific primer binding.  3-5 replicate PCR reactions were combined and 
purified with the QIAquick PCR Purification Kit (QIAGEN, 28104) and submitted to the 
Johns Hopkins Deep Sequencing & Microarray Core Facility for sequencing. 
 
PacBio Sequencing and Analysis 
2-3 μg of purified PCR product was submitted to the Deep Sequencing & 
Microarray Core Facility. Quality Control was performed on a 1:200 dilution of samples 
using a Bioanalyzer (Agilent, G2939A) High Sensitivity DNA Assay. Products were size 
selected for the expected size range of 1-3kb because of populations of both very low and 
high MW products. 1 SMRT cell was sequenced per sample.  8000 to 40,000 ccs reads 
were acquired from each SMRT cell.  
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Sequencing reads were filtered and trimmed in the SMRT Analysis v4.0 software 
(Gordon et al. 2015).  This program generates the circular consensus sequence (ccs), then 
selects full-length reads that pass a quality threshold. These reads were aligned to 
chromosome 14 (hg38 assembly) using HISAT2 (Pertea et al. 2016).  Gene models were 
then assembled with StringTie (Pertea et al. 2015; Pertea et al. 2016; Kim et al. 2015).  
StringTie was first run for individual samples using the default settings except the 
minimum isoform fraction was set to 0.01 instead of 0.1.  To build a gene model for all 
human reads, StringTie --merge was run with the minimum isoform fraction set to 0.05. 
HISAT2 and StringTie results were viewed in IGV (Thorvaldsdottir et al. 2013; 
Robinson et al. 2011).  
2.4.7 Immunofluoresence 
 
HeLa FLP-in cells were plated in chamber slides. The following day, media was removed 
and the cells were washed with PBS and incubated with 4% paraformaldehyde (PFA) for 
20 minutes. Slides were washed twice for 5 minutes with PBS, once with 0.5% Triton in 
PBS for 15 minutes, washed two more times with PBS.  Slides were blocked in 10% goat 
serum in PBS for 30 minutes (Sigma G0923) and incubated with primary antibody for 1 
hour at room temperature.  Then they were washed with PBS three times for five minutes 
and incubated in secondary antibody for one hour at room temperature. They were 
washed again three times with PBS and then a coverslip with Dapi/Vectashield was 
added to the slide. Primary antibodies and dilutions were mouse anti-myc clone 4A6 
(Sigma 05-724), 1:200 and rabbit anti-TRF2 (Novus Biologicals NB110-57130), 1:800.  
Secondary antibodies goat anti-mouse IgG1 cross-adsorbed to AlexaFluor 488 
(Invitrogen #21121) or goat anti-rabbit IgG highly cross adsorbed to AlexaFluor555 
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(Invitrogen# 21429) were diluted 1:400. Slides were imaged on a Nikon Eclipse Ni 
microscope with a 60x objective using the NIS Elements software. 
2.4.8 Southern Blotting 
 
Genomic DNA Isolation 
Cell pellets were washed in PBS then stored at -80°C until use.  Pellets were resuspended 
in 300 μl SNET (20mM Tric-Cl, pH 8.0, 5 mM EDTA, 500mM NaCl, 1% SDS) 
supplemented with 400 μg/ml proteinase K and lysed on a shaking platform at 55°C 
overnight.  Proteins were removed with an equal volume of phenol:chloroform, 1:1, with 
gentle rocking for 30 minutes.  After a 5-minute spin at 13,000xg, the aqueous layer was 
transferred to a new tube and DNA was precipitated with an equal volume of 
isopropanol.  DNA was pelleted by spinning for 15 minutes in a microfuge at 13,000xg, 
washed with 70% ethanol and dried to remove residual ethanol.  Pellets were resuspended 
in 50-100μl TE supplemented with RNaseA with shaking at room temperature overnight. 
 
Sample Preparation, Electrophoresis, and Transfer 
Genomic DNA was digested in 50μl reactions in 1X CutSmart Buffer (NEB) and 2 μl 
MseI (NEB R0525M) overnight at 37°C.  Double-stranded DNA was measured using the 
Qubit dsDNA BR Assay kit per the manufacturer instructions.  Samples were prepared in 
1X Blue Juice loading dye (1% SDS, 0.3% Bromophenol Blue, 250mM EDTA, 40% 
sucrose) and normalized to the concentrations calculated from the Qubit measurements. 
10ng of 2-log DNA ladder (NEB) is loaded in the first lane.   
 Samples were run on a 0.7% TTE (20X TTE=1.78 M Tris base, 0.57 M taurine, 
0.01 M EDTA) gel containing 0.5μg/ml ethidium bromide at 45 V overnight for about 20 
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hours. The gel was denatured for 30 min in 0.2 M sodium hydroxide (NaOH), 0.34M 
NaCl and neutralized for 30 min in 1.5 M NaCl, 0.5 M Tris, pH 7.0. Gels were 
transferred by vacuum blotting (Boekel Appligene) at ≤60 mbar onto Amersham 
Hybond-N+ membrane (GE Healthcare) in 10X SSC (1.5 M NaCl, 0.17 M sodium 
citrate) for 1 hr. The membrane was UV-crosslinked twice using the auto-crosslink 
function (UV Stratalinker 2400, Stratagene) and prehybridized for 1–2 hr in Church 
buffer (0.5 M Tris, pH 7.2, 7% SDS, 1% bovine serum albumin, 1 mM EDTA).   
 
Probe labeling and hybridization 
25ng of JHU821 plasmid and 2-log ladder are labeled by random priming according to 
the manufacturer protocol using α32P-dGTP and cleaned up using a G50 mini spin 
column.  Membranes were hybridized overnight with JHU821 and 2-log ladder probe, 











 The mechanism by which TIN2 affects telomere length is not known. Most short 
telomere disease mutations affect telomerase activity, biogenesis, or stability, so we 
explored potential mechanisms through which TIN2 could be affecting telomere 
elongation by telomerase.  We noted that TIN2 interacts directly with TPP1, a telomerase 
processivity factor that binds directly to telomerase (Houghtaling et al. 2004; Wang et al. 
2007; Xin et al. 2007). Therefore, we investigated the TIN2-TPP1 interaction as a 
potential mechanism of TIN2 regulation of telomere length. 
TPP1 interacts directly with the TEN domain of telomerase reverse transcriptase 
(TERT) through its TEL-patch region in its OB-fold (Figure 3.1) (Nandakumar et al. 
2012; Sexton et al. 2012; Zhong et al. 2012). TPP1 forms a heterodimer with POT1, 
which is the single-stranded binding component of the shelterin complex (Ye, 
Hockemeyer, et al. 2004; Liu, Safari, et al. 2004; Chen et al. 2017; Rice et al. 2017). 
POT1 binds single-stranded telomere repeats specifically with its two N-terminal OB 
folds (Lei et al. 2004; Loayza et al. 2004).  Together, TPP1/POT1 recruits telomerase to 
the single-stranded telomeric DNA and stimulates its processivity (Xin et al. 2007; Zhang 
et al. 2013; Sexton et al. 2014). Deletion of TIN2 in mouse cells causes loss of TPP1 and 
POT1 telomeric localization to telomeres as detected by immunofluroesence and ChIP 
(Takai et al. 2011). Expressing a TIN2 allele that does not bind TPP1 cannot rescue the 
TPP1/POT1 localization defects observed in TIN2 knockout cells (Frescas & De Lange 
2014). Additionally, TPP1ΔC22 which lacks the TIN2 binding domain cannot localize to 
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the telomere when expressed in human cells (O’Connor et al. 2006). We asked whether 
the TIN2-TPP1 interaction also affects telomerase activity. 
 Telomerase has two core components: a reverse transcriptase (TERT) and an 
RNA component (TR). Telomerase binds the 3’ telomere end and uses its internal RNA 
template to align to the single stranded DNA and add nucleotides (Greider & Blackburn 
1989; Autexier & Greider 1995). Once it fills in a telomere repeat from its template, it 
translocates to add more repeats or stops and dissociates (Greider 1991). The term 
processivity refers to the average number of telomere repeats added in a single telomerase 
binding event.   
While it is not precisely known how many telomeres get elongated each cell 
cycle, or how many repeats are added with each telomere addition event, we know that 
the processivity is important for maintaining telomere length. Changes to either 
telomerase catalytic activity or to its processivity are each sufficient to cause short 
telomere disease in humans (Nelson & Bertuch 2012).  Several mutations in TERT that 
specifically reduce processivity have been identified in short telomere diseases (Alder et 
al. 2011; Gramatges et al. 2013). Mutations affecting the TPP1 TEL-patch also cause 
disease through reduced TPP1-telomerase association resulting in decreased processivity 
(Kocak et al. 2014; Bisht et al. 2016). 
Processivity can be measured using an in vitro telomerase assay, called the direct 
telomerase activity assay (Greider 1991; Sun et al. 1999; Chen & Greider 2003). This 
assay is performed by providing telomerase a short telomere primer in excess and 
allowing it to add telomere repeats for a defined amount of time. A more processive 
enzyme will have longer extension products, while a less processive enzyme will have 
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shorter extension products. The intensity of the bands on a gel corresponds to the amount 
of product synthesized at that length. Relative processivity can be determined by 
calculating the proportion of high molecular weight products to lower molecular weight 
products. While processivity is traditionally measured by pulse-chase assays, using a vast 
primer excess assures that the long products come from processivity and not from 
dissociation and re-binding events (Chen & Greider 2003; Wang et al. 2007). 
Telomerase assays have often been performed using enzyme reconstituted in 
rabbit reticulocyte lysates, because telomerase is not soluble (Gillis et al. 2008).  An 
alternative method is to overexpress components in cells and assay telomerase in cell 
lysates (Cristofari & Lingner 2006; Latrick & Cech 2010). While using purified proteins 
allows more control over concentration and stoichiometry, co-expression of telomerase 
assay components in cell lines ensures proper folding and interactions of the target 
proteins.  A cell-based system overexpressing TERT/TR, POT1, and TPP1 was 
developed by Nandakumar et. al., and it showed robust telomerase processivity which 
was used to identify the effects of the TEL-patch residues (Nandakumar et al. 2012).  We 
built on this idea, generating a system overexpressing TERT/TR, TPP1, and POT1, where 
we were able to introduce different TIN2 constructs with or without the patient mutations 
to define their effects on telomerase processivity.  
We found that wild-type TIN2 stimulates telomerase processivity over that of 
TPP1/POT1 alone.  This stimulation was not seen with the K280E patient mutation. TIN2 
stimulation of telomerase required functional TPP1/POT1, as it was not detected in cell 
lines with TPP1 TEL-patch mutations or cell lines only overexpressing TERT/TR. We 
conclude that TIN2 cooperates with TPP1/POT1 to stimulate telomerase processivity. 
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These data suggest that TIN2/TPP1/POT1 function as a heterotrimeric processivity 
complex that binds ssDNA and stimulates telomerase. 
 
3.2 RESULTS 
3.2.1 Generation of Telomerase Assay Cell Lines 
 
To generate telomerase assay cell lines, we wanted to create uniform expression 
of each of the different components: TERT, telomerase RNA (TR), TPP1, and POT1. 
Early experiments used transfection of multiple plasmids expressing individual 
components, but this resulted in high variability in expression and experimental results. 
To remove sources of variability, we decided to generate cell lines uniformly 
overexpressing these components where TIN2 could be introduced. 
First, we generated a construct with self-cleaving 2A peptides to clone TPP1-
POT1-TERT into a single polycistronic expression cassette. This polycistron ensures 
even expression of the protein components. 2A peptides allow co-expression of proteins 
from a single transcript by causing ribosome skipping over a specific sequence (Ryan et 
al. 1991; Ryan & Drew 1994; Doronina et al. 2008; Szymczak et al. 2004). This method 
has been used to improve expression cassettes for making induced pluripotent stem (iPS) 
cells, among other applications (Carey et al. 2009). The 2A peptides leave a small tag on 
the downstream proteins, so TERT was added in the last position of the expression 
cassette because it is not functional with C-terminal tags (Counter et al. 1998; Armbruster 
et al. 2001; Chiba et al. 2017). 3X-FLAG tagged TERT, TPP1, and POT1 constructs 
were a kind gift from the JK Nandakumar and the Cech lab.  The FLAG tag allows all 
three proteins to be detected together in a western blot.  We also created a construct with 
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a TPP1 TEL-patch mutation, E169A/E171A (Nandakumar et al. 2012), that will be 
referred to as TPP1TEL and a construct expressing TERT only to test the dependence of 
TIN2 on TPP1/POT1 (Figure 3.1A).  
We cloned the polycistronic expression cassettes into the pcDNA5-FRT vector for 
use in the TREx FLP-in system, and flanked the cassette with restriction sites for cloning 
into other expression vectors (see Materials and Methods).  These FLP-in cell lines have 
an FRT site located at a single genomic locus along with a promoter and start codon for 
the selectable marker.  The FRT expression vectors contain a selectable Hygromycin 
marker lacking a promoter and ATG start codon, so they will only survive selection if the 
plasmid is integrated at the correct genomic locus. By using this system, we can ensure 
that each cell has one copy of the expression construct.  
Before incorporating the protein expression cassettes, we transduced 293TREx 
FLP-in cell lines with a telomerase RNA expressing lentivirus and selected high TR 
expressing clones for uniform background overexpression of TR. Then, we used the FLP-
in system to integrate each expression construct into a single genomic locus. The three 
resulting cell lines will be referred to as TPP1/POT1/TERT, TPP1TEL/POT1/TERT, or 
TERT only (Figure 3.1B).  
We validated protein expression by a FLAG western blot in parallel with 
transfection of the individual components and saw that all three proteins were expressed 
(Figure 3.1C). We did not observe high molecular weight species that would indicate 
failure of 2A peptide cleavage. Interestingly, we noticed that TERT expression is much  
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higher in the polycistronic context than alone.  We tested a GFP-2A-TERT construct to 
see if the polycistronic context would give higher TERT expression, but that cell line also  
had low TERT expression. We have not been able to determine if this difference is an 
artifact of the expression system or due to stabilization of the telomerase by TPP1/POT1 
(Appendix G). We also observed two unidentified bands in the polycistron cell lines that 
may be TERT degradation products based on their size.  
Telomerase assays were performed by incubating 3-5μl of clarified cell lysates 
with a telomere seed primer a5 (TTAGGGTTAGCGTTAGGG) (Lei et al. 2005; Wang et 
al. 2007) at 30°C for the indicated time. Products were purified and separated on a 
sequencing gel (see Materials and Methods).  In telomerase assays of the parent cell lines, 
stopped after 10, 20, or 40 minutes, the TPP1/POT1/TERT cell line has higher 
processivity, indicated by the intensity of the higher molecular weight bands, than the 
TPP1TEL/POT1/TERT or TERT only cell lines (Figure 3.1 D).  
3.2.2 Method of Processivity Calculation 
 
Telomerase processivity can be quantified in several ways.  Telomerase catalytic 
activity of the enzyme is assessed by measuring the intensity of the first repeat, and 
specific activity refers to the total activity relative to the amount of telomerase in the 
reaction. Processivity is independent of the amount of enzyme in the reaction and only 
depends on the ratio of different size bands within a lane. 
When the major pause bands can be discriminated on a gel, each band is 
quantified and normalized to the number of radioactive dGTPs incorporated and to the 
total intensity of repeats below it. Plotting this relative intensity against repeat number 
generates a line with negative slope, as telomerase has a higher probability of dissociating 
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over time.  In this method of processivity calculation, the telomerase processivity is 
defined by the repeat number where the intensity is half maximal.  For more details, see 
Materials and Methods.    
 A simpler way to measure processivity is also necessitated by the inability to 
separate and quantitate high molecular weight bands generated by processive telomerase.  
This relative processivity measure called the “+15 method” measures the relative 
intensity of the high molecular weight bands from repeat 15 and above, and expresses it 
as a ratio to the total intensity of a lane.  This method does not account for the number of 
radioactive dGTP incorporated into the high molecular weight bands, which should be 
considered a caveat for this measurement.  However, it has successfully been used to 
identify changes in processivity (Nandakumar et al. 2012). 
3.2.3 TIN2 forms a complex with TPP1/POT1/TERT 
 
To determine whether TIN2 interacts with the TPP1/POT1/telomerase complex, 
we performed reciprocal co-immunoprecipitations of myc-tagged TIN2 and FLAG-
TPP1/POT1/TERT.  We transfected TIN2S, TIN2M, TIN2L, or the full-length gene with 
or without the K280E patient mutation, and GFP as a negative control.  
Using a myc antibody to pull down TIN2, we saw that TPP1, POT1, and TERT 
all co-immunoprecipitated with TIN2 but not with the GFP control (Figure 3.2A). Using 
the reciprocal FLAG immunoprecipitation, we pulled down FLAG-TPP1, FLAG-POT1, 
FLAG-TERT complexes and saw a co-immunoprecipitation of all TIN2 isoforms 
(Appendix H). The patient mutations did not affect the association of TIN2 with these 
complexes.  These assays, however, are not quantitative, so minor changes in the 
distribution of TIN2-containing complexes may not have been detected. 
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Figure 3.2 TIN2 forms a complex with TPP1/POT1/TERT.  
(A) myc-TIN2 was transfected into TPP1/POT1/TERT cell lines. TIN2 complexes were 
immunoprecipitated with anti-myc. Top: western blot with myc and FLAG on myc-TIN2 
immunocomplexes. Bottom: input. (B) Telomerase assays performed on myc-TIN2 immunocomplexes.   
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 The telomerase enzyme that co-immunoprecipitates with TIN2 in these 
experiments is fully functional, active enzyme (Figure 3.2B). There is some background 
activity in the GFP negative controls (Figure 3.2A and B, asterisk). Still, all of the TIN2 
IP samples had high amounts of telomerase activity, indicating that the TIN2-TPP1-
POT1-telomerase complexes are active.  Assays on TIN2 immunocomplexes were highly 
variable, however, so tests of telomerase function with TIN2 were performed on the 
whole cell lysates. 
 
3.2.4 TIN2 stimulates telomerase processivity 
 
 To examine the effects of TIN2 on telomerase cell lines, we used several methods 
to introduce TIN2 into the telomerase assay cell lines. First, we transfected either the 
TIN2 full-length gene or individual TIN2 isoforms, and second we added increasing 
amounts of recombinantly expressed and purified TIN2L to prepared telomerase assay 
lysates. These assays are highly sensitive to stoichiometry of TIN2 with TPP1/POT1, but 
by using these approaches we have assayed telomerase in an excess of TIN2. By 
transfecting high amounts of TIN2 expression constructs, we hope to have all cells in the 
population transfected, thereby removing fluctuations in the experimental conditions. 
 Transient transfection of the full-length TIN2 gene (TIN2-FL) showed that all 
three isoforms were expressed with or without the patient mutations (Figure 3.3A).  
Direct telomerase assays on the TPP1/POT1/TERT cell line showed a surprising increase 
in telomerase processivity when cells were transfected with TIN2-FL compared to 
transfection of GFP (Figure 3.3B).  The processivity stimulation was evident from the 
appearance of higher molecular weight bands at the 10-minute timepoint.  TIN2-FL with  
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the K280E mutation, however, was unable to stimulate telomerase, and appeared to have 
slightly lower processivity than the GFP control.  While we predicted that the TIN2 
mutation might decrease processivity, we had not anticipated that TIN2 might actually 
stimulate telomerase beyond the processivity stimulation provided by TPP1/POT1. 
 
Figure 3.3 TIN2-FL stimulates telomerase processivity.  
(A) Western blots of duplicate transfections of TIN2-FL, TIN2-FL K280E, or GFP into TPP1/POT1/TERT 
cell lines. (B) Telomerase assays of transfections  from A, stopped after 5 or 10 minutes. LC, loading and 
purification control; +1, 2, etc, repeat number; *=nonspecific band. (C) Quanitification of assays in B. The log 
of normalized activity was plotted against repeat number according to the decay method of calculating 
telomerase processivity.  Slopes and processivity values are displayed below the graph. 
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To determine if specific isoforms might be required for processivity stimulation 
by TIN2, we independently transfected the three different isoforms with an N-terminal 
myc tag into the TPP1/POT1/TERT cell line.  We found a 10-20% stimulation of 
telomerase processivity with each of the isoforms.  This result indicates that all three 
isoforms are able to stimulate telomerase processivity.  It should be noted that there was 
no effect of C-terminally tagged TIN2S or TIN2L on telomerase in TPP1/POT1/TERT 
cell lines in previous assays, suggesting the C-terminal tag may interfere with TIN2 
function (Appendix I). 
3.2.5 TIN2 stimulation of processivity requires TPP1/POT1 
 
 To test whether processivity stimulation is dependent on TPP1/POT1/TERT, we 
repeated the transfections in the TPP1TEL/POT1/TERT cell lines and in the TERT only 
cell lines. We found no stimulation of telomerase processivity in these cell lines (Figure 
3.4, B and C).  These results indicate that TIN2 stimulation of telomerase is dependent on 
TPP1/POT1. 
 As a third method to examine telomerase processivity, we added recombinant 
TIN2L, expressed and purified from E. coli, to telomerase assay lysates. First, we tested 
whether the N-terminally his-MBP-tagged TIN2L co-immunoprecipitates with 
TPP1/POT1/TERT by adding increasing amounts of his-MBP-TIN2L to the lysates and 
performing a FLAG immunoprecipitation (Figure 3.5A). We saw that his-MBP-TIN2L 
co-immunoprecipitated with the FLAG-complexes.  
Using the range of TIN2 concentrations that bound to the FLAG complexes in the 
immunoprecipitations, we then added increasing amounts of his-MBP TIN2L to 
TERT/TPP1/POT1 lysates and tested telomerase processivity. Purified MBP alone served 
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as a negative control. We saw that 375nM TIN2 stimulated telomerase processivity 
(Figure 3.5 B and C). Adding more TIN2 beyond that amount did not further stimulate 
telomerase, indicating that the stoichiometry between TIN2, TPP1, and POT1 is more  
 
Figure 3.4 TIN2 isoforms stimulate telomerase through TPP1/POT1.   
(A) Western blots of myc-TIN2 isoform triplicate transfections into TPP1/POT1/TERT or 
TPP1TEL/POT1/TERT cell lines.  TIN2 isoforms are indicated on the right of the myc blots. FLAG proteins 
are also labeled. (B) Telomerase assays stopped after 40 minutes of elongation.  *=sample lost in 
preparation. (C) +15 quantification of samples in B and from results in the TERT only cell line. Data from 
each cell line was analyzed with a one-way ANOVA and Bonferroni’s Multiple Comparisons test against 
the GFP control. ***, p<0.001; **, p<0.01; *, p<0.05. 
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important than the total amount of TIN2 in the reaction.  MBP did not stimulate 
telomerase, indicating that the processivity stimulation is specific to the TIN2 protein and 
not due to the buffer content or increased protein in the samples. This data supports the 
conclusion from our other experiments that TIN2 completes the TPP1/POT1 telomerase 
processivity complex.  
 
3.3 DISCUSSION 
 We have shown that all three TIN2 isoforms form a complex with TPP1/POT1 
and telomerase and stimulates telomerase processivity through interaction with 
TPP1/POT1.  The reproducible 10-20% increase in processivity suggests that TIN2 
completes the TPP1/POT1 telomerase processivity complex. TIN2 could stabilize both 
the TPP1-telomerase interaction and the POT1-ssDNA interaction. This could result in a 
higher percentage of fully assembled, processive telomerase complexes or extend the 
lifetime of telomerase on the telomeric DNA.   
 While all three TIN2 isoforms stimulated telomerase in a TPP1-dependent 
manner, potential functional differences between the isoforms cannot be discounted.  We 
saw stimulation of telomerase in N-terminally but not C-terminally tagged TIN2 
constructs (Appendix I), and the differences in the three isoforms are at the C terminus. 
This supports our hypothesis that the TIN2 C-terminus is functionally important. Further 
studies on the isoform differences and the C-terminal extensions in TIN2M and TIN2L to 
identify interaction partners or tertiary structures are required to understand the 
mechanism of TIN2 function.    
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In addition to our finding of TIN2’s participation in the processivity complex, it 
has previously been shown that TIN2 is required for several specific TPP1/POT1 
functions in cells. TIN2 floxed mouse cell lines show less telomeric TPP1/POT1 
localization by immunofluorescence (IF) and trigger ATM and ATR DNA damage 
responses (Takai et al. 2011).  Knockdown of TIN2 by shRNA in HeLa cells similarly 
showed less TPP1/POT1 localization to the telomere by IF and was associated with less 
telomerase detected at the telomere by ChIP and FISH (Abreu 2010).  Similarly, 
disruption of TIN2 telomeric localization by mutating the FxLxP TRF1 binding motif 
interaction prevents TPP1/POT1 accumulation at telomeric DNA in mouse cells, but 
localization can be rescued by tethering TIN2 to TRF2 (David Frescas & de Lange 
2014a).  Finally, deletion of the TPP1 binding region from mouse TIN2 also prevents 
localization of TPP1/POT1 to telomeres detected by IF (Frescas & De Lange 2014). 
 
 
Figure 3.6 TIN2 completes the TPP1/POT1 processivity complex. 
TIN2 may be stimulating processivity by completing the telomerase processivity complex. Forming a 
complex with TIN2 could enhance TPP1/POT1 stimulation of telomerase as well as enhance POT1-ssDNA 
interactions and aid in localization to the telomere through TIN2 interactions with TRF1 and TRF2. 
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Because TIN2 binds TRF1, TRF2, and TPP1/POT1, it is generally referred to 
simply as a “tether” or “bridging” molecule required to bring together the shelterin 
components, stabilizing them at the telomere. Our data suggest that TIN2 is part of the 
TPP1/POT1 complex. One main function of this heterotrimeric subcomplex is to bind 
single-stranded DNA and regulate telomerase, and TIN2 serves an important role of 
localizing the complex to the telomeres through its TRF1 and TRF2 interactions (Figure 
3.6). 
 Further evidence for a TPP1/POT1/TIN2 heterotrimeric complex is the apparent 
stoichiometry of the proteins.  We saw in the recombinant TIN2 assays that TIN2 only 
stimulated telomerase when it reached a certain concentration, which by co-
immunoprecipitation appeared to be stoichiometric with TPP1/POT1.  Excess TIN2 
could not further stimulate telomerase, probably because there were no more free 
TPP1/POT1 complexes to interact with.  Our data suggest the mechanism for TIN2 
stimulation of telomerase is that TIN2 stabilizes the telomerase and processivity factor 
complexes by completing the heterotrimeric TPP1/POT1/TIN2 complex.  POT1 is less 
stable in the absence of TPP1, which is consistent with their function as a heterodimer 
(Chen et al. 2017).  TIN2 appears to cooperate with TPP1/POT1 function, suggesting 
they are actually a higher order heterotrimeric complex. 
  Previous work showed that TPP1/POT1 increases telomerase processivity (Wang 
et al. 2007), and we observed 10-20% stimulation on top of the TPP1/POT1 contribution 
when including TIN2.  Our results are similar to recent observations of the telomerase 
processivity factors in Tetrahymena. Tetrahymena p50 and Teb1 were identified as 
telomerase processivity factors, just as TPP1/POT1 are known to stimulate human 
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telomerase (Min & Collins 2009). Subsequently it was found that additional factors from 
Tetrahymena further stimulate telomerase processivity and are part of the p50/Teb1 
complex (Upton et al. 2017). 
Based on a cryo-electron microscopy (cryo-EM) structure of the Tetrahymena 
telomerase holoenzyme, it was found that Teb1 forms an RPA-like complex, TEB, with 
two previously unknown proteins, Teb2 and Teb3 (Jiang et al. 2015). While p50-Teb1 
contribute to the majority of the processivity stimulation, including the complete TEB 
complex in telomerase assays resulted in even further stimulation of telomerase 
processivity (Upton et al. 2017).  Our findings with TIN2 and TPP1/POT1 are analogous 
to this observation. 
 Alterations in both telomerase activity and processivity are sufficient to cause 
disease in humans. We have shown here that TIN2 patient mutations have defects in the 
stimulation of telomerase through TPP1-POT1, suggesting that the mechanism of disease 
may be loss of telomerase processivity.  Many TIN2 patients, however, experience rapid 
telomere shortening in one generation, which cannot be accounted for by loss of 
telomerase function alone. Given that TIN2/TPP1/POT1 form a single-stranded binding 
complex, we suggest they may also have roles in coupling telomere replication with 
telomerase activity. Uncoupling these processes may cause the rapid telomere loss that is 
seen in many TIN2 patients. In the next chapter we discuss how telomeric single-stranded 
binding proteins may coordinate telomere end protection, telomerase regulation, and 
telomere replication. 
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3.4 MATERIALS AND METHODS 
3.4.1 Telomerase Expression Constructs  
TPP1-POT1-TERT 
Starting plasmids were a kind gift from the Cech Lab, p3x-Flag-POT1-cDNA6/Myc-
HisC, p3x-Flag-TPP1-cDNA6/Myc-HisC, p3x-Flag-TERT-cDNA6/Myc-HisC.  Note that 
TPP1 starts at Met87 (Nandakumar et al. 2012). We generated TPP1TEL by engineering 
the E169A/E171A mutation with site-directed mutagenesis primers A150/A151. We used 
the expression vector pcDNA5-Lox-Stop-Lox, which was generated by Jon Alder by 
adding an additional lox-bGH-lox after the bGH polyA signal in pcDNA5-FRT. This was 
initially chosen because we tried to express hTR from the same vector after TPP1-POT1-
TERT cassette, but this alone did not produce sufficient hTR expression for telomerase 
activity.  
Plasmids were designed with unique restriction sites BstBI and NotI flanking the 
polycistronic expression cassette for cloning into different vectors.   
The cloning of the TPP1/POT1/TERT expression cassettes required a two-step 
approach because of the repetitive nature of the 3X-FLAG tags and 2A peptide 
sequences. In the first round of Gibson Assembly, POT1-2A-TERT was generated. POT1 
was amplified with primers A76/A77, and TERT was amplified with A78/A71.  The 
overlapping repetitive region with 3xFLAG-T2A-3XFLAG was synthesized as an IDT 
gBlock (A74, Appendix A).  Because of the repetitive nature and GC-content of the 
codons in this region, we were required to engineer silent mutations, which are indicated 
in Appendix A.  The pcDNA5-LSL vector was digested with AgeI/SbfI. Digested vector 
and POT1 and TERT amplicons were gel purified.  50ng vector was assembled with 3-
fold molar excess of the POT1, gBlock, and TERT inserts using 2X Gibson Master Mix 
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according to the manufacturer protocol (NEB E2611). Reactions were transformed into 
NEB5α cells and colonies were screened for correct insertion of the fragments. 
 In the second round of Gibson Assembly, TPP1-P2A was incorporated into the 
POT1-2A-TERT cassette (Figure 3.6B).  TPP1 or TPP1TEL was amplified with primers 
A79/A80. The vector backbone from round one was opened with AgeI restriction digest.  
TPP1 amplicons and opened vector were gel purified.  50 ng backbone was assembled 
with 3-fold molar excess of TPP1 amplicon and 3X-FLAG-P2A gBlock. 
PCR amplifications were performed with Phusion High-Fidelity DNA polymerase 
(NEB M0530) using the manufacturer protocols with the following changes.  For all 
reactions, 5X GC buffer was used instead of HF buffer. TERT reactions were 
supplemented with 3.5 μl DMSO, and POT1 reactions were supplemented with 3.5 μl 
DMSO and 2.0 μl MgCl2 that was supplied by the manufacturer.  Reactions were 
performed in 50μl volumes.  The PCR program was:  
Denature  0:30  98°C  
38 Cycles:  0:30  98°C  
0:15  48°C (POT1) or 55°C (TERT, TPP1)  
0:60  72°C  
  Final Extension 7:00 72°C 
 
TPP1/POT1/TERT and TPP1TEL/POT1/TERT were screened it by restriction digest and 
sequence verified using primers T7, bGH-Rev, and A87-A97. We found one T>C base 
change in TPP1/POT1/TERT, but it was a silent mutation that did not change the coding 
sequence. TERT only expression constructs were generated by PCR amplification of the 
3XFLAG-TERT with A120/A121 and Gibson Assembly into pcDNA5-LSL.  Sequence 




construct was subsequently flipped into a single genomic FRT site in one of the high hTR 
overexpressing clones using the Flp-in system (Invitrogen). 
3.4.3 Quantitative RT-PCR of hTR 
 
To measure hTR expression levels, RNA was isolated from FUPW-hTR 
transduced clones with the RNeasy Kit (Qiagen, 74104) following the manufacturer 
protocol with a 1 hour on-column DNase digestion using the RNase-free DNase kit 
(Qiagen, 79254) to remove any genomic DNA.  1 μg of RNA was reverse transcribed 
from with random hexamer primers using the SuperScript III First Strand Synthesis Kit 
(Qiagen, 18080-051).  Quantitative RT-PCR was performed on a Bio-Rad CFX96 
thermocycler with approximately 5ng cDNA, 1X IQ SYBR Green Supermix (Bio-Rad, 
1708884BUN), and 5 μM primers. Samples were measured in triplicate.  Every plate 
contains a no template control for background and a no-RT control for DNA 
contamination.  hTR primers are GGAAGCTTGCTAGCGCACCGGGTTG and GTT 
TGCTCTAGAATGAACGGTGGAA.  hTR levels were normalized to ARF3, which is 
measured with primers A21 and A22 (Cristofari & Lingner 2006) (Appendix A). Relative 
quantification (Δ(ΔCt) Method) was used to determine hTR expression level relative to 
non-transduced cells.  
3.4.4 Preparation of telomerase assay lysates 
 
Transfections 
For TIN2 transfections, 5 x 105 cells of the respective telomerase assay cell line 
were plated in each well of a 6-well dish.  The next day, the indicated TIN2 or GFP 
construct was transfected with Lipofectamine 2000 (Invitrogen 11668019) following the 
manufacturer protocol, using 8 μl Lipofectamine 2000 and 2.5 μg DNA per well diluted 
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in Opti-MEM (Gibco 31985088, 51985034).  Transfected cells were incubated for 48 
hours before harvesting. 
 
Preparation of cell lysates 
 Cells were disrupted by pipetting and transferred to a conical tube, pelleted at 
500xg for five minutes, washed once with PBS, then resuspended in 1ml 1X PBS and 
transferred to a microfuge tube. Cells were pelleted again with a quick spin in a benchtop 
centrifuge, all supernatant was removed, and pellets were resuspended in 100μl 1X 
CHAPS buffer (10mM Tris-HCl, pH 7.5, 1 mM MgCl2, 1mM EGTA, pH 8.0, 0.1 mM 
Benzamidine, 5mM β-Mercaptoethanol, 0.5% CHAPS, 10% glycerol).  Cells were either 
snap-frozen on dry ice until lysis or lysed immediately on ice for 30 minutes, with 
occasional vortexing.  Lysates were clarified by a 10 minute spin at 8000xg at 4°C and 
transferred to a new tube.  A western blot aliquot was taken and telomerase assays were 
either performed immediately or clarified lysates were snap frozen and stored at -80°C 
until use.  Telomerase activity appears stable after storage at -80 and several freeze-thaw 
cycles, but freeze-thaw should be kept to a minimum. 
3.4.5 Western Blotting 
 
Western blot samples were made with 10 μl telomerase assay lysate, 10μl 4X LDS 
(Invitrogen, NP0008), 4 μl 500mM DTT, and 16 μl water and denatured at 65°C for 10 
minutes. 10-15 μl prepared samples were separated by reducing, denaturing PAGE 
electrophoresis on a 4-12% Bis-Tris gel (NuPAGE, NP0323) in 1X MOPS buffer 
(Invitrogen, NP0001) and transferred to PVDF (Immobilon FL, IPFL00010) in 1X 
NuPAGE Transfer Buffer (Invitrogen, 00061) with 10% Methanol.  3 μl of the SeeBlue 
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Plus2 (Thermo, LC5925) prestained ladder are included to estimate molecular weight. 
Membranes are then blocked in 1X TBS + 0.1% Tween20 (TBST), 5% milk (Bio-Rad 
170-6404) for 30 minutes at RT or overnight at 4°C.  Primary antibody was diluted in 
blocking buffer and incubated with agitation at room temperature for 30 minutes to 2 
hours. Primary antibodies and concentrations are as follows: mouse anti-myc 4A6 
(Millipore 05-24), 1:2000; rabbit anti tubulin (Abcam, ab6046), 1:5000; mouse anti-
FLAG M2 (Sigma F1804), 1:5000.  Blots were washed 3 times with TBST and incubated 
with the appropriate secondary, anti-rabbit HRP or anti-mouse HRP (Cell Signaling), 
diluted 1:10,000 in TBST. After 3 washes with TBST, blots are developed with 
SuperSignal West chemiluminescence substrate (Thermo, PI34095) and imaged on an 
ImageQuant LAS4000 imager. 
3.4.6 Co-Immunoprecipitation of TIN2 Complexes 
 
Immunoprecipitations were carried out using either anti-FLAG M2 affinity gel 
(Sigma A2220) or anti myc resin, either anti-c-myc agarose (Pierce 20168) or anti-myc 
tag 4A6, agarose conjugate (Millipore 16-219). Beads were prepared for reactions by 
transferring 5-20 μl slurry per reaction into a microfuge tube, washing 3-5 times with 1X 
PBS, equilibrating in 1X CHAPS, and aliquoting to tubes for each sample.  45 μl lysate 
was added to each tube and brought up to suitable volume (~300-400μl) using 1X PBS. 
Samples were incubated in an end-over-end mixer at 4°C for two hours.  Beads were 
pelleted with a quick spin, washed 4 times with 300 μl 1X CHAPS buffer, and either 
resuspended in either 1X LDS loading dye for western blot analysis or equilibrated in 1X 
telomerase assay buffer for telomerase assays. 
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3.4.7 Direct Telomerase Activity Assay  
 
Lysates were prepared as described above.  For recombinant TIN2L assays, 
telomerase assay lysates were prepared without transfection, and recombinant TIN2L was 
diluted in 1X telomerase assay buffer to the specified concentration.  Recombinant 
TIN2L concentrations were measured using the Qubit Protein Assay Kit (Invitrogen 
Q33211). 
Five microliters (5 μl) of the indicated lysate was incubated with a5 primer (49) 
and 0.5 mM dTTP, 0.5 mM dATP, 2.92 μM dGTP, and 0.33 μM α32P-dGTP  (Perkin 
Elmer) in telomerase buffer (50 mM Tris-Cl, 30 mM KCl, 1 mM MgCl2, 1 mM 
spermidine). Reactions were incubated for the indicated time minutes at 30°C, terminated 
with 120 μl stop buffer (20mM EDTA, 10mM Tris), spiked with 500-750 cpm end-
labeled 18-mer purification control per reaction.  
Protein was removed by adding 140μl 1:1 phenol:chloroform, vortexing briefly, 
and spinning at max speed for 2 minutes. The upper aqueous layer was transferred to a 
new tube with 60μl 7.5M sodium acetate (NH4OAC; Sigma A2706) and 5 mg glycogen 
(Life Technologies, AM9510) for ethanol precipitation. 540μl ethanol was added to the 
tubes and samples were allowed to precipitate on dry ice for one hour or at -80°C 
overnight. Tubes were spun at 4°C for 30 minutes at maximum speed to pellet the DNA 
and pellets were washed with 500μl 70% ethanol. After all residual ethanol was removed, 
telomerase products were resuspended in 4 μl water and 4 μl 2x formamide loading dye, 
denatured at 100°C for 5 minutes, and separated on a sequencing gel (10% acrylamide, 7 
M urea 1x TBE), at 90 W for 1.5 hr.  The gel was dried onto filter paper, exposed to a 
phosphor screen, and scanned on a Storm 825 scanner. 
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3.4.8 Quantitation of Direct Assays 
 
Telomerase assays were analyzed with ImageQuantTL software using two 
different methods: the decay method and the 15+ method. 
The Decay Method 
Telomerase pause bands were quantified in the 1D gel analysis function of 
ImageQuantTL.  After lane definition, detection of bands with a fixed with of 9 px, and 
background subtraction using the rolling circle method of correction, band intensities 
were exported to Excel. Because this method requires the ability to quantitate individual 
bands, it is only used here in assay run from 5 to 15 minutes. 
The decay method calculation (Latrick & Cech 2010) is based on a probability p 
that telomerase will add repeat n+1 after adding repeat n, and a probability (1-p) that it 
will stop adding repeats after n. Assuming p is constant for every value of n, the fraction 
of telomerases that add at least n repeats, f(>n), in a single binding event is pn.  The step 
between two bands on the telomerase assay gel, Nn+1-Nn, directly correlates to the p.  By 
plotting the relative activity of each band as ln(Nn>n) against repeat number n, the slope 
correlates to this step and therefore to the processivity. Processivity values are 
determined as the value of n for which half of the primers were elongated to n or more 
repeats, which equals ln(1/2)/ln(p), or ln(1/2)/slope.  Thus, the value of processivity with 
plotting the relative activity for each repeat against repeat number is 0.693/slope. Slopes 
were determined by linear regression.  
To generate this plot, the pixel intensities are first corrected for the number of 
radioactive guanosines incorporated.  Total lane counts (TLC) are calculated by adding 
together intensities for all bands.  The “fraction left behind” or FLB is then calculated for 
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each n by summing all intensities n0 through n and dividing the sum by the TLC.  Plotting 
ln(1-FLB) against repeat number n generates a line whose slope, m, corresponds to the 
processivity value of 0.693/m.   
 
The 15+ Method 
 Processive telomerase generates many large products that are not resolved on the 
telomerase assay sequencing gels.  To determine the processivity of telomerase in these 
samples, the scanned gels are loaded into ImageQuantTL Analysis Toolbox. Using the 
grid tool with the number of columns equaling the number of lanes in the gel, two boxes 
were generated: one covering bands 1 through 14 and a second covering bands 15+.  
Intensities were exported to Excel and the processivity was calculated as (15+ 
Intensity)/[(1-14 Intensity) + (15+ Intensity)] for each lane.  The resulting value shows 
relative processivity for samples run on the same gel. 
 Replicate samples were plotted using GraphPad Prism software and we used a 
One-Way ANOVA with paired t-tests to determine if there were significant differences 
between the samples. Results from paired t-tests were only considered if the One-Way 
ANOVA showed that the samples had significantly different values (p<0.05). 
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Chapter 4.  Implications of telomere-specific single-stranded binding 
complexes on replication and elongation of telomeres 
4.1 Single-stranded DNA at the telomere 
Telomeres have several sources of single-stranded DNA (ssDNA) and pose 
unique challenges that are addressed by specialized DNA binding complexes.  The 3’ 
overhang is a conserved feature of telomeres (Henderson & Blackburn 1989), but the 
length of the overhang is variable between organisms. While humans have 3’ overhangs 
on the order of 100s of nucleotides (Makarov et al. 1997), the overhang in yeast is 
approximately 10 nucleotides (Wellinger et al. 1993) and only a few nucleotides in 
Tetrahymena and other ciliates (Roth & Prescott 1985; Jacob et al. 2001). 
In all of these organisms, however, a much larger amount of telomeric ssDNA is 
exposed during DNA replication. Additionally, the repetitive and G-rich nature of 
telomere sequences poses a challenge to the replicative polymerases and there is evidence 
of telomeric replication fork stalling or collapse (Miller et al. 2006; Bosco & de Lange 
2012). Replication Protein A (RPA) is the abundant, canonical single-stranded binding 
protein that carries out many functions in DNA replication and repair.  However, there 
are also several single-stranded DNA binding complexes that perform specific functions 
at the telomere. These specialized complexes are much lower in abundance than RPA but 
have higher specificity for G-rich telomere sequences. 
Telomere specific functions of these specialized complexes include telomere end 
protection, telomere replication, and telomerase regulation.  Telomere end protection can 
be seen as the prevention of binding RPA from coating the telomeric ssDNA and 
triggering a DNA damage response.  This is typically defined by cells displaying a 
telomeric DNA damage response when a telomere protein is absent or non-functional. 
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The telomeric DNA damage response is characterized by ATM or ATR signaling, 
telomeric localization of 53BP1 and/or γH2AX, or by chromosome fusions.  While TRF2 
deletion triggers an ATM-mediated DNA damage response (Karlseder et al. 1999; 
Karlseder et al. 2004), deletion of TRF1 or POT1 leads to an ATR-mediated DNA 
damage signal, which is reflective of RPA accumulation due to fork stalling (Bosco & de 
Lange 2012; Denchi & de Lange 2007). 
Telomeric single stranded binding complexes (SSBs) also have a role in 
replication, specifically in coordinating the completion of telomere replication by the 
lagging strand replication machinery.  This is necessary to normal complete lagging 
strand synthesis of the telomeric DNA.  There is another process known as C-strand fill-
in, which is the synthesis of new DNA complementary to de novo sequence added by 
telomerase, which is necessary for net elongation of both telomere strands.  C-strand fill-
in is also orchestrated by the lagging strand replication machinery. Disrupting complexes 
involved in telomere replication can result in excessive single-stranded telomeric DNA, 
ATR signaling, and a higher percentage of metaphase chromosomes with signal-free ends 
or a cytogenetic phenomenon known as “fragile telomeres”.   
Finally, there are also single-stranded DNA binding complexes that regulate 
telomerase activity.  These proteins are required for telomerase localization to the 
telomere and have important roles in stimulating telomerase processivity.  Defective 
telomerase processivity complexes have decreased telomerase processivity in vitro as 
well as decreased telomere length in cells. 
These functions of single-stranded telomere DNA metabolism are managed by 
several different SSBs.  Some of the telomere specific SSBs have overlapping roles and 
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may be redundant in cells. These telomere SSBs can be organized into two main classes.  
The first telomere specific SSB to be identified were the CST complexes, named for the 
Saccharomyces cerevisiae Cdc13-Stn1-Ten1 complex, or t-RPA. Both human and yeast 
CST share the conserved role of stimulating DNA polymerase alpha (pol α) at the 
telomere (Hughes et al. 2000; Qi & Zakian 2000; Wan et al. 2009). The second class is 
telomerase processivity complexes, which coordinate telomerase activity at the telomere.  
Across organisms, these two complexes vary in their contributions to telomere end 
protection, telomere replication, and telomerase recruitment. 
4.2 RPA is the global SSB in eukaryotic cells 
RPA is essential for DNA replication, replication fork progression, DNA damage 
response, and DNA repair (Wold et al. 1987; Wold 1997).  RPA is a well conserved 
heterotrimeric protein complex. RPA binds ssDNA in a non-sequence specific manner 
and modulates enzymes involved in DNA metabolism.   
The three subunits of RPA are RPA70, RPA32, and RPA14, also known as 
RPA1, RPA2, and RPA3, respectively. These proteins contain a total of six OB-fold 
domains, designated A-F, which contribute to DNA binding, protein interactions, and 
RPA heterotrimerization (Figure 4.1). RPA14 is the smallest subunit and consists of a 
single OB-fold, OB-E.  The three proteins form a tight structurally conserved 




RPA70 is a 70 kDa protein that contains four OB-fold domains and is the main 
DNA binding subunit. RPA70 uses OB-A and OB-B to bind an 8-nt footprint of DNA, 
and assembled RPA engages OB-C from RPA70 and OB-D from RPA32 to bind a 32nt 
DNA footprint with nanomolar to subnanomolar binding affinity (C. Kim et al. 1994). 
Dynamic association and dissociation of these OB folds with ssDNA contributes to 
different binding footprints and movement along the ssDNA (Fanning et al. 2006). 
The N-terminal RPA70 OB-fold, OB-F, and the RPA32 winged-helix-turn-helix 
(wHTH) domain contribute to interactions with RPA-interacting proteins. OB-F interacts 
with a number of factors, including T-antigen, p53, DNA polymerase α, Rad52, ATRIP, 
Rad9, and Mre11 (Wold et al. 1989; Collins & Kelly 1991; Dornreiter et al. 1992; Han et 
al. 1999; Hicks et al. 2003; Prakash & Borgstahl 2012).  The RPA32 wHTH interacts 
with UNG2, XPF, and Rad52 (Mer et al. 2000), among others.   
Interestingly, RPA was first observed to stimulate DNA polymerase α 
processivity by Tsurimoto and Stillman in 1989.  Including RPA in activity assays has 
also been found by others to stimulate processivity of polymerase α (Tsurimoto & 
Stillman 1989; Melendy & Stillman 1993).  It was later shown that two distinct activities 
of RPA are required for stimulation of polymerase α: the interaction with ssDNA through 
the OB-A and OB-B DNA binding domain as well as the N-terminus of RPA70 
(Dornreiter et al. 1992; Braun et al. 1997). The mechanism of RPA stimulation of other 
DNA maintenance enzymes is not as well understood, but likely requires both the ssDNA 
binding affinity of RPA and the protein-protein interactions.  
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4.3 CST complexes 
 CST complexes are conserved across many organisms but are best described in 
the budding yeast Saccharomyces cerevisiae where they were first identified.  ScCST is 
also known as a telomere-specific RPA, or t-RPA, because of its homology to the RPA 
trimer (Gao et al. 2007).  It also functions as an end-binding complex and recruits 
telomerase in yeast (Evans & Lundblad 1999; Qi & Zakian 2000). 
 ScCST, or t-RPA, consists of Cdc13, Stn1, and Ten1 (Figure 4.1).  Cdc13 has a 
similar domain structure and organization to RPA70 (Gao et al. 2007), but the third OB-
fold is the sole DNA binding domain of the complex (Mitton-Fry et al. 2004).  Cdc13 
also homodimerizes through its OB2 (Sun et al. 2011; Mason, Jennifer J Wanat, et al. 
2013), and associates with Stn1/Ten1 with a heterotrimerization core homologous to that 
in RPA (Sun et al. 2009; Mason, Jennifer J. Wanat, et al. 2013). Stn1 is homologous to 
RPA32, but contains two rather than one wHTH domain.   
 While the overall domain structure of this t-RPA is very similar to that of RPA, 
the differences contribute to its unique functions.  t-RPA binds an 11-nt footprint of the 
yeast telomere sequence, GTGTGGGTGTG, with picomolar affinity (Lewis et al. 2014; 
Altschuler et al. 2011; Anderson et al. 2002). Cdc13 recruits telomerase through protein 
interaction with EST1 (Evans & Lundblad 1999; Qi & Zakian 2000), and the interaction 
with Stn1-Ten1 is thought to bring in DNA polymerase α for C-strand fill in (Qi & 
Zakian 2000).  
 In other organisms that have CST, the Stn1-Ten1 subunits are highly conserved, 
but the large “C” subunit is very divergent (Rice & Skordalakes 2016; Price et al. 2010).  
Because it is the main DNA binding subunit, the divergence corresponds with varying 
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DNA binding affinities and changes in specificity.  Still, the CST complexes share a role 
in recruiting and stimulating DNA polymerase α at lagging strand telomeres, which is 
important for telomere replication (Qi & Zakian 2000; Stewart et al. 2012). 
 The Tetrahymena thermophila proteins p75, p45, and p19 also form a CST 
complex (Wan et al. 2015).  This CST complex binds a 24-nt footprint of sequence 
(TTGGGG)4 (Wan et al. 2015).  Not only is Tetrahymena CST important for telomere 
replication, it has also been recently found as part of the telomerase holoenzyme (Jiang et 
al. 2015), suggesting a possible mechanism for coupling telomerase activity with lagging 
strand telomere replication and/or C-strand fill-in. 
 Mammalian CST complexes have a more global role in DNA replication at G-rich 
DNA sequences.  The main DNA binding component is CTC1, which does not bind 
telomeres specifically but instead shows a preference for G-rich DNA. Human Stn1/Ten1 
was originally purified as a DNA polymerase α accessory factor and named AAF 
(Goulian et al. 1990; Goulian & Heard 1990), but was later found to be in a complex with 
CTC1 and shown to be homologous to CST proteins.  CST can be found at G-rich sites 
across the genome and is thought to help with restart of stalled replication forks (Stewart 
et al. 2012; Wang et al. 2014).  It has been suggested that because CST has a higher 
affinity for ssDNA than DNA polymerase α, forming a ternary complex enhances 
polymerase affinity for ssDNA and improves its activity (Goulian & Heard 1990).  
Mutations in CTC1 and STN1 have been identified in patients with the disease Coats 
Plus, which has many features of short telomere syndromes plus additional phenotypes 
that may be due to additional replication defects (Keller et al. 2012; Anderson et al. 2012; 
Gu & Chang 2013; Simon et al. 2016).  
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4.4 Other telomeric SSBs in telomere length maintenance 
Unlike yeast CST, mammalian CST does not perform end protection functions in 
non-replicating cells (Stewart et al. 2012).  Instead, this role is assumed by the POT1 
protein in complex with TPP1 and TIN2.  POT1 specifically binds telomeric ssDNA on 
the telomeric G-strand.  Like RPA70, POT1 contacts the ssDNA with two OB-folds that 
comprise the DNA binding domain (Lei et al. 2004; Loayza et al. 2004).  POT1 
heterodimerizes with the TPP1 protein, and the heterodimer forms the telomerase 
processivity complex that is important for both recruitment and stimulation of telomerase 
at telomeric DNA (Figure 4.1). 
We found that TIN2 cooperates with TPP1 and POT1 in stimulating telomerase.  
TIN2, TPP1, and POT1 appears to function as a heterotrimeric DNA binding complex 
that regulates telomerase activity.  In addition to other evidence that TIN2 is important 
for TPP1/POT1 function in vivo (See Chapters 1.5.2 and 3.3), recent experiments that 
individually knocked out shelterin components found that POT1, TPP1, or TIN2 
knockout affected localization of the other respective TIN2/TPP1/POT1 components 
more than other shelterin components as detected by ChIP and immunofluoresence (Kim 
et al. 2017).  These results led the authors to propose that TIN2/TPP1/POT1 forms a 
subcomplex within shelterin. 
TIN2 participation in this complex could improve the POT1-ssDNA interaction in 
a manner similar to the increased binding affinity of the complete RPA complex 
compared to RPA70 alone.  Similarly, TIN2 participation in the complex may improve 
the TPP1-telomerase interaction, resulting in the observed increase in processivity. TIN2 
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is also important for localizaing the complex to telomeres through its interactions with 
TRF1 and TRF2. 
While TIN2-TPP1-POT1 seem to function as a heterotrimeric complex like RPA, 
they are likely not a canonical RPA.  Recent structural studies of the TPP1-POT1 
interaction do not follow the canonical protein-protein interaction interface of RPA 
complexes (Rice et al. 2017; Chen et al. 2017).  There is no structural information about 
TIN2 at this time. Additionally, TIN2 interacts with TPP1 but has not been shown to 
interact directly with POT1 (Houghtaling et al. 2004; Takai et al. 2011; David Frescas & 
de Lange 2014a).  While it cannot be ruled out that the three proteins coexpressed may 
take on a different structure, it appears that TIN2-TPP1-POT1 is a divergent telomeric 
SSB. 
Tetrahymena have homolous proteins to TPP1 and POT1, Tpt1 and Pot1, 
respectively.  These proteins bind the single-stranded telomere overhang and are 
structurally analogous to TPP1/POT1, but do not appear to play a role in telomerase 
stimulation (Jacob et al. 2007; Linger et al. 2011; Premkumar et al. 2014). Instead, 
another set of homologous proteins, Teb1 and p50 are involved in stimulation of 
telomerase. Teb1 is a telomere-specific single-stranded binding protein with homology to 
POT1 and to RPA70 (Upton et al. 2017; Zeng et al. 2011) and stimulates telomerase 
processivity along with its binding partner p50 (Hong et al. 2013; Jiang et al. 2015). It 
has been argued that Tpt1/Pot1 and p50/Teb1 compete for the short 3’ telomere overhang 
(Chan et al. 2017), but it could be that they have specialized roles in end protection and in 
regulation of the ssDNA generated during DNA replication. Interesting advances in the 
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Tetrahymena telomerase holoenzyme structure revealed that Teb1 is actually part of a 
larger complex, TEB, which is described below (Jiang et al. 2015; Upton et al. 2017). 
4.5 Tetrahymena telomerase holoenzyme structure  
Recent advances in studying the Tetrahymena thermophila telomerase 
holoenzyme structure by cryo EM have led to some interesting discoveries.  First, that the 
telomerase holoenzyme contains both the CST complex (p75, p45, and p19) and the 
telomerase processivity complex (p50/Teb1) (Jiang et al. 2015). Second, the telomerase 
processivity factor Teb1 actually forms a complex with previously unidentified 
components Teb2 and Teb3, which form the RPA-like complex TEB (Jiang et al. 2015; 
Upton et al. 2017).  
Tetrahymena Teb1/p50 had been previously identified as a telomerase 
processivity complex (Witkin & Collins 2004; Witkin et al. 2007; Min & Collins 2009), 
where Teb1 stimulates telomerase in a p50 dependent manner.  The p50 protein is 
thought to be analogous to TPP1, as it interacts directly with telomerase analogous to the 
TPP1 TEL-patch interaction with the telomerase TEN domain (Schmidt et al. 2014; Jiang 
et al. 2015).  Teb1 is an OB-fold containing telomere-specific single-stranded binding 
protein with similarities to POT1 and RPA70 (Zeng et al. 2011; Upton et al. 2017). Once 
the Teb2 and Teb3 components of TEB were identified, however, the full TEB complex 
was shown to stimulate processivity more than Teb1 alone (Upton et al. 2017)  
Including the complete TEB complex with Teb2 and Teb3 appears to favor 
stability of the fully assembled telomerase holoenzyme (Upton et al. 2017).  The 
contribution of Teb2/Teb3 to telomerase stimulation above the known processivity factor 
is similar to what we have observed with TIN2 and TPP1/POT1 (see Chapter 3). By 
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couples telomerase activity with lagging strand replication (Figure 4.2). We have 
illustrated how the DNA, either during replication or after being synthesized by 
telomerase, could concurrently interact with CST to coordinate lagging strand replication 
and telomerase to coordinate elongation. 
 
4.6 Coupling of telomere replication and telomerase activity 
 It has been known for many years that there is a relationship between telomerase 
elongation of telomeres and the lagging strand replication machinery. Deletion of lagging 
strand DNA polymerases α or δ, but not the leading strand polymerase ε, prevented de 
novo telomere addition by telomerase in cells (Diede & Gottschling 1999).  Mutations in 
lagging strand polymerases or other factors involved in Okazaki fragment maturation 
lead to excessive telomeric single-stranded DNA, but also to increased telomere lengths 
(Carson & Hartwell 1985; Parenteau & Wellinger 1999; Grossi et al. 2004; Budd et al. 
2006).  Evidence connecting telomerase elongation of the telomeres and DNA replication 
is reviewed in (Greider 2016).  Also, the telomere specific SSBs are specific for the G-
strand, which is replicated by the lagging strand replication machinery, rather than the C-
strand (Sections 4.3 and 4.4). 
 Given their high affinity for telomeric DNA, telomere-specific SSBs will likely 
compete with canonical RPA as a replication fork progresses into telomere sequence. 
Additionally, we know that the two classes of telomere-specific SSB are involved in both 
DNA replication and in telomerase elongation of telomeres, which are two processes that 
are known to be coupled. Coupling of lagging strand replication and telomere elongation 
is important in two circumstances.  First, C-strand fill-in must be coordinated by CST for 
net elongation of telomeres where the G-strand was elongated by telomerase. Second, if 
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telomere SSB complexes may be required to help continue Okazaki fragment synthesis as 
well as to stimulate telomerase. The implication of the Tetrahymena holoenzyme 
structure is that these two processes are physically coupled, and this may be conserved 
across organisms.  
Considering telomerase and lagging strand machinery as coupled, there may be 
multiple ways to disrupt the telomere length equilibrium.  The simplest way is loss of 
telomerase function, which may not affect telomere replication, but will result in a 
gradual telomere shortening over time due to insufficient or absent telomere elongation.  
This type of telomere shortening is what is observed in families with telomerase 
mutations who experience progressive telomere shortening over multiple generations 
(Figure 4.4A).  
 Defective telomere SSBs could cause uncoupling of telomerase and replication, 
however, leading to two distinct scenarios.  Defective or uncoupled lagging strand 
replication machinery may allow unregulated telomere elongation (Figure 4.4B).  This 
leads to excessive ssDNA and DNA damage signaling as well as increased telomere 
lengths without effective C-strand fill-in. This is a phenotype observed with POT1 
deletion or POT1 mutants that cannot bind DNA (Takai et al. 2011; Takai et al. 2016).  
Similarly, mutations in many components of the lagging strand replication machinery 
cause telomere elongation and increased telomeric single-stranded DNA (Greider 2016).  
Complete uncoupling of telomere replication from telomerase activity could result 
in more drastic effects at the telomere.  This uncoupling could cause both defective 
lagging strand replication and a failure to recover from telomeric replication fork collapse 




4.7 Replication fork collapse as a possible mechanism of telomere shortening with 
TIN2 mutants 
 The degree of telomere shortening in patients with de novo TIN2 mutations is 
severe and cannot be explained by loss of telomerase processivity alone (Mary Armanios 
& Blackburn 2012; Savage et al. 2008).  Indeed, the telomere length of these patients 
compared to their unaffected parents and siblings suggests there must be a mechanism of 
telomere truncation in these patients.  Unrepaired replication fork collapse in the telomere 
could explain this drastic telomere loss. 
 There is evidence of the POT1 complex having a role in replication fork 
progression. Certain POT1 mutants that cannot bind DNA cause an ATR-mediated DNA 
damage response, fragile telomeres, and increased telomere replication fork stalling 
detected by DNA combing (Pinzaru et al. 2016). Interestingly, cells expressing these 
POT1 mutants also have a decreased association of CST at telomeres detected by ChIP. 
Evidence in studies of TIN2 also point toward possible roles in replication. Mouse cells 
carrying the TIN2 K267E allele, analogous to the human K280E mutation, have 
increased ATR signaling, signal-free ends (SFEs), and fragile telomeres. Finally, 
disruption of TIN2 interaction with HP1γ has been proposed to cause defects in sister 
telomere cohesion. This is observed in FISH as an increase in the distance between sister 
telomeres before cell division (Canudas et al. 2011). This apparent defect in cohesion 




investigate replication defects.  Using quantitative fluorescence in situ hybridization (q-
FISH) on metaphase chromosomes from the TIN2 isoform overexpression cell lines, we 
will determine whether there are abnormal telomere maintenance events that would not 
be visible by Southern blot.  By probing telomeres and scoring metaphases for 
chromosome fusions, fragile telomeres, and signal-free ends, we can learn about the 
telomere dysfunction in TIN2 and TIN2-K280E cells expressing the different isoforms.  
Telomere truncations might be seen as uneven sister telomere lengths, if the truncation is 
large enough to detect within the sensitivity of this method.  
The ability of TIN2 mutants to cause telomeric replication fork collapse will also 
be tested using the ADDIT (addition of de novo initiated telomeres) assay (Lee et al. 
2015).  While we may observe a lower percentage of de novo telomeres elongated or 
shorter tracts of new telomere sequence in TIN2 mutant-expressing cells compared to 
wild-type, it may also be possible to observe fork collapse events as large deletions in the 
telomere seed sequence.  Comparison to the results in mTR knockout cells is an 
important control to determine if any changes observed are due to something other than 
the lack of telomerase. Fork collapse has not been tested before in this assay, so a positive 
control such as hydroxyurea or other damage agents that cause fork collapse will also be 
important for interpreting the data.  It is important to note that the ADD-IT assay is set up 
in mouse cells, which only express one isoform of TIN2.  
 Another way telomeric DNA replication has been studied is by single-molecule 
analysis of replicating DNA (SMARD) by DNA fiber combing (Norio & Schildkraut 
2001).  This method can follow the progression of replication origins through the 
telomere, and has been used to identify replication fork stalling in telomeres in TRF1 and 
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POT1 knockout conditions (Sfeir et al. 2009; Pinzaru et al. 2016). This is a technique we 
can employ with our HeLa cell lines expressing TIN2 isoforms and mutants or with 
CRISPR knock-in cell lines carrying TIN2 patient mutations. 
 It has been nearly a decade since TIN2 mutations were first identified in short 
telomere patients with Dyskeratosis Congenita.  While there remain many unanswered 
questions about the endogenous functions of TIN2 and the mechanism of telomere 
shortening in the TIN2 patients, our findings of multiple TIN2 isoforms in human cells 
and the cooperation of TIN2 with the TPP1/POT1 processivity complex provide a new 




Appendix A. Primers used in this project 
# Name Purpose sequence 
A1 V5_C (-) sequencing accgaggagagggttagggat 
A2 M13 (+) sequencing gtaaaacgacggccag 
A3 M13 (-) sequencing caggaaacagctatgac 
A4 TIN2 stop>Ser (+) SDM cacagagcaaaaggagtcgaacccagctttcttg  
A5 TIN2 stop>Ser (-) SDM caagaaagctgggttcgactccttttgctctgtg  
A6 TIN2 K280E (+) SDM ctaggggaggccatgaggagcgccccacag  
A7 TIN2 K280E (-) SDM ctgtggggcgctcctcatggcctcccctag  
A8 Tin2 R282S (+) SDM ggaggccataaggagagccccacagtcatg  
A9 Tin2 R282S (-) SDM catgactgtggggctctccttatggcctcc  
A10 Tin2 R282H (+) SDM gaggccataaggagcaccccacagtcatgctg  
A11 Tin2 R282H (-) SDM cagcatgactgtggggtgctccttatggcctc  
A14 trunc_tin2_A overlap extension cgttgtaaaacgacggccag 
A17 trunc_tin2_D overlap extension attttgagacacgggccaga 
A18 Ub (+) sequencing tcagtgttagactagtaaattg 
A19 trunc_TIN2_B2 overlap extension agctgggttcttatggcctcccctagt 
A20 trunc_TIN2_C2 overlap extension ggccataagaacccagctttcttgtac 
A21 ARF3 + qRT-PCR  tcaccaccatccctaccatt 
A22 ARF3 - qRT-PCR aggtggcctgaatgtaccag 
A23 ins_tin2L_B overlap extension caagcaattctccttttgctctgtggc 
A24 ins_tin2L_C overlap extension caaaaggagaattgcttggattgctac 
A25 ins_tin2L_D overlap extension tgctgggttcaaaggtctagaactgtc 
A26 ins_tin2L_E overlap extension agacctttgaacccagctttcttgtac 
A27 TS TRAP aatccgtcgagcagagtt 
A28 RP TRAP cccttacccttacccttaccctta  
A29 TSK1 TRAP aatccgtcgagcagagttaaaaggccgagaagcgat 
A30 K1 TRAP atcgcttctcggcctttt  
A31 primer a5 Direct Assay ttagggttagcgttaggg 
A32 TIN2 qPCR+ qRT-PCR gtcagaggctcctgtggatt 
A33 TIN2 qPCR- qRT-PCR cagtgctttctccagctgac 
A34 GMPR-proximal 




Homology Arm (-) 
gibson assembly tcgtttgttcctaagtgttgttcagctgtgcc 
A36 NeoR (+) gibson assembly caacacttaggaacaaacgacccaacaccg 
A37 NeoR (-) gibson assembly tacgaagttattgcatctcaattagtcagcaaccatag 
A38 TINF2-proximal 





Homol Arm (-) 
gibson assembly tggagctccaccgcggtggccaaaaggagtgagtggaacaga
gttg 




A41 US-homology arm 1 (-
) 
gibson assembly ttgagatgcaccggggcggagacaaggatg 
A42 sv40 ori (+) gibson assembly tccgccccggtgcatctcaattagtcagcaaccatag 
A43 sv40 ori (-) gibson assembly ggctgcaggttttgcaaaagcctaggcctcc 
A44 PuroDTK(+) gibson assembly cttttgcaaaacctgcagccaacgccac 
A45 PuroDTK (-) gibson assembly atgcttcaataccatagagcccaccgcatc 








A48 V5 qPCR Reverse qRT-PCR agagggttagggataggcttac 
A49 TIN2 V5 F qRT-PCR ctgaaggagaacccagttgac 
A50 280X-V5-F qRT-PCR acgaagagttcagtcccaatg 
A51 open pENTR F TIN2L ctccttttgctctgtggcag 
A52 open pENTR R TIN2L aacccagctttcttgtacaaagttggcattataagaaagc 
A53 genomic TINF2 
promoter 
  
A54 genomic TINF2 
promoter 
  
A55 TPP1 F1 gibson assembly ccggactctagcgtttaaactaatacgactcactatagggag 
A56 TPP1 R1 gibson assembly ctgcttcagcaggctgaagttggtggccttgtcatcgtcatccttg 
A57 POT1 F1 gibson assembly cgatgacaaggccaccaacttcagcctgctgaagcaggccggc
gacgtggaggagaaccccggccccgagatgtctttggttccagc
aac 
A58 POT1 R1 gibson assembly gcaggtcagcaggctgcccctgcccttgtcatcgtcatccttg 





A60 TERT R2 gibson assembly gtatgctatacgaagttatctcagtccaggatggtcttg 
A61 oligo-dT adapter cDNA synthesis caggaaacagctatgactttttttttttttttttttt 
A62 clone seq primer F screening  ctaggaagtcgagcctcacg 
A63 PAC sequence F  gagtacaagcccacggtgc 
A64 PAC sequence R  cttgcgggtcatgcaccag 
A65 u1hTR with Acc65I 
sites 
cloning gatcggtacctcgaggtcgacggtatcgataagc 
A66 u1hTR rev with NOT1 cloning gcggtggcggccgctctag 
A67 u1hTR F with Not1 cloning gatcgcggccgcaacctcgaggtcgacggtatcgataagc 
A68 u1hTR Rev with 
Acc65I 
cloning gatcggtaccggaccagcttctttgggagagaac 
A69 TPP1 F2-AgeI gibson assembly attctgcagcccgggactaaccggtcgatggcaggttcggggag
gctgg 
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A70 TPP1 R2 AgeI opened gibson assembly gctgaagttggtggccttgtcatcgtcatccttg 
A71 TERT R-NheI site gibson assembly gcggcatgtctagcctgcaggaacaccgctagctcagtccagga
tggtcttg 
A72 PAC Crispr Top  caccgggcggggtagtcggcgaacg 












made to reduce 
GC content and 
repetitiveness for 





























 gibson assembly agg agt act aga agc cta tct cat gga ttc tg 
A74-
R 
 gibson assembly ggc cac cag ctc ctt cag gc 
A75 tpp1FLAG-p2a-pot1 gibson assembly 
 



























a75-F  gibson assembly gca ctt tct gat gga tgc aca gc 
a75-R  gibson assembly tgt tgc tgg aac caa aga cat acc g 
A76 POT1 F age1 gibson assembly attctgcagcccgggactaaccggtatgtctttggttccagcaaca 
A77 POT1 R gblock gibson assembly ccatgagataggcttctagtactcctg 
A78 Tert F gblock gibson assembly gcctgaaggagctggtggcccgag 
A79 TPP1 F BstBI gibson assembly gacggtatcgattctgcagcccgggactaattcgaagccaccatg
gcaggttcggggagg 
A80 TPP1R gblock gibson assembly gacatcggagttggctcagaccctggc 
A81 upstream CRISPR top  caccgcgccaccaggggcgtagcca 
A82 upstream CRISPR 
bottom 
 aaactggctacgcccctggtggcgc 
A83 downstream #1 top  caccgctgtgcctaaaagggttagc 
A84 downstream #1 bottom  aaacgctaacccttttaggcacagc 
A85 downstream #2 top  caccgtcaaccctgctaaccctttt 
A86 downstream #2 bottom  aaacaaaagggttagcagggttgac 
A87 FOR_1 sequencing gaggaccaggagcatcagg 
A88 FOR_2 sequencing tagggttgccctgcaagaat 
A89 FOR_3 sequencing tggagatattgttcgctttca 
A90 FOR-4 sequencing ggggaatcagggtcttacca 
A91 FOR-5 sequencing tgtgagatctggccacgaag 
A92 REV-6 sequencing agatgccgagagctcccag 
A93 REV-7 sequencing aaccatagcgtcagggagg 
A94 REV-9 sequencing ctgtcggaagcagaggtca 
A95 REV-9 FOR sequencing tgacctctgcttccgacag 
A96 REV_10 sequencing gcctcttcgacgtcttccta 
A97 REV_11 sequencing tacaagatcctcctgctgca 
A98 hU6 sequencing gag ggc cta ttt ccc atg att cc 
A99 Primer A making TINF2 
downstream 
gtaggaatgaagtggaagtccagg 








A102 Primer D making TINF2 
downstream 
aaccctgctccatagagcccaccgcat 
A103 Primer E making TINF2 
downstream 
gctctatggagcagggttgaaagcctg 
A104 Primer F making TINF2 
downstream 
taaagagatgctggggctttctg 
A105   cattcctactaaactacttgcagagct 
A106   cagcctcgactgtgccttctagttg 
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A107    
A108    
A109 TINF2_CRSP_scn_L3 TINF2 myc tag 
screen 
aggtacccagagccgacag 
A110 TINF2_CRSP_scn_R3 TINF2 myc tag 
screen 
gcagagatcgcagaaactcc 
A111 JA Homology Arm 1  cggcgacgtttaaagctga 
A112 JA Homology Arm 2  atcccgcccctttctttct 
A113 HA Seq Primer R  agcgtaatctggaacatcgt 
A114 TPP1 del F 0611 deletion agcccgggactaagtctttggttcca 
A115 TPP1 DEL R 0611 deletion tggaaccaaagacttagtcccgggct 
A116 TPP1-FLAG-Rev 0611 minus 
POT1 
cttgtcatcgtcatccttgtagtcgatgtcatgatcttta 
A117 TERT-2A-Fwd 0611 minus 
POT1 
tacaaggatgacgatgacaagggcaggggcagcctgctg 
A118 K280R + SDM ctaggggaggccatagggagcgccccacag 
A119 K280R - SDM ctgtggggcgctccctatggcctcccctag 
A120 TERT fwd gibson gcagcccgggactaagactacaaagaccatgacgg 
A121 TERT rev gibson gcatgtctagcctgcatcagtccaggatggtcttg 
A122 myc fwd  caaaaacttatttctgaagaagatctg 
A123 RACE Adapter 3' RACE gactcgagtcgacatcg 
A124 RACE-oligodT 3'RACE gactcgagtcgacatcgtttttttttttttttttttt 
A125 100bp arm F1  acagggagttgccagaagcc 
A126 100bp arm R1  cggaaaatgttccacgcagc 
A127 30bp arms F2  aacccggagggaccgcct 
A128 30bp arms R2  agcgtagagctgcgggacc 
A129 HindIII-myc  gcgtttaaacttaagcttcgccgaccatggaacaaaaacttatttct
g 
A130 TIN2M+Not1 rev  gactcgagcggccgcctacccatcccctttcc 
A131 K280X+  ctaggggaggccattaggagcgccccacag  
A132 K280X -   ctgtggggcgctcctaatggcctcccctag  
A133 eGFP-2a-TERT F1  ctcggcatggacgagctgtacaagggcaggggcagcctgctga
c 
A134 eGFP-2a-TERT R1  cagctcctcgcccttgctcaccatggtggcttcgaattagtccc 
A135 eGFP F2  agcccgggactaattcgaagccaccatggtgagcaagggcgag 
A136 eGFP R2  cgcaggtcagcaggctgcccctgcccttgtacagctcgtccat 
A137 TIN2M overlap 
Forward 
gibson tgtacaaaaaagcaggcaccgctacgcccctggtggcg 
A138 TIN2M Overlap 
Reverse 
gibson tgtacaagaaagctgggtttgagtgcagagaaacacaggctcc 
A139 pcDEST40 open  aacccagctttcttgtaca 
A140 pcDEST open rev  ggtgcctgcttttttgtacaaac 
A141 #1 5'UTR_TIN2_1 PacBio 
mouseTIN2 
gtg cag atg aga gaa gcg 
A142 #1 5'UTR_TIN2_2 PacBio 
mouseTIN2 
tgg gtt gaa cga aag gag 
A143 Exon1_Tin2_1 PacBio 
mouseTIN2 




TIN2M cloning ggt gcc tgc ttt ttt gta caa ac 
A145 pcDNA-
DEST40F_TIN2M 
 tcg aac cca gct ttc ttg 
A146  TIN2MF_pcDNA-
DEST40 




 tac aag aaa gct ggg ttc gag tgc aga gaa aca cag 
gct cc 
A148 c-V5 Fwd insert Cterm tag cctaaccctctcctcggtctcgattctacgtgatagaactaaaatgc
tctc 
A149 c-V5-Rev insert Cterm tag accgaggagagggttagggataggcttacccaaaggtctagaa
ctgtctc 
A150 TEL patch Fwd  cggaagccgaacgccttcgcctcccagtccg 
A151 Tel Patch Rev  cggactgggaggcgaaggcgttcggcttccg 
A152 mTIN2_F amp from cDNA atggccccacctccaggg 
A513 mTIN2_R1 amp from cDNA ggacactacgggatgtagtcaca 
A154 mTIN2_R2 amp from cDNA ctacgggatgtagtcacaaaacatgggg 
A155 pcDNA5_open_F gibson clone  agcggccgctcgagtctag 
A156 pcDNA5_open_R gibson clon ccagatcttcttcagaaataag 
A157 mTIN2 gib F gibson tatttctgaagaagatctggatggccccacctccaggg 
A158 mTIN2 gib R gibson tctagactcgagcggccgctctacgggatgtagtcacaaaacatg
g 
A159 K267E fwd SDM tcggcaaaggcgtgccatgaagagcggccca 
A160 K267E rev SDM tgggccgctcttcatggcacgcctttgccga 
A161 K267X fwd SDM caaaggcgtgccattaagagcggcccac 
A162 K267X rev SDM gtgggccgctcttaatggcacgcctttg 
A163 R269S fwd SDM ggcgtgccataaagagagccccacagtcatgctac 
A164 R269S rev SDM gtagcatgactgtggggctctctttatggcacgcc 
A165 R269H fwd SDM ggcgtgccataaagagcaccccacagtcatgctac 
A166 R269H rev SDM gtagcatgactgtggggtgctctttatggcacgcc 
A167 TPP1 ΔC22 Open F TPP1 ΔC22 aagctgccaggcttcctcccgactacaaagaccatgacgg 
A168 TPP1 ΔC22 open R TPP1 ΔC22 accgtcatggtctttgtagtcgggaggaagcctggcagc 
A169 FLAG-TPP1 + overlap  gctgaagttggtggccctaggcttgtcatcgtcatccttg 
A170 TPP1 ΔC22 F2  gggaggaagcctggcagc 
A171 TPP1 ΔC22 R2  tcagactacaaagaccatgacgg 
A172 overlap   gctgccaggcttcctccctcagactacaaagaccatgacgg 
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Appendix B.  TIN2 Multiple Sequence Alignments 
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Appendix C. TIN2 isoform sequencing results.  See also Figure 2.3.  
The coverage track shows the coverage of TIN2 exons (labeled at bottom).  There is one predominant 
isoform expressed.  The aligned reads are shown in blue and gray. One line represents a single read. Blue = 
aligned sequence; Gray = not covered; Black=InDels.  Note the frequency of Indels from pacbio 
sequencing. InDels were not included in Figure 2.3 but were left in this figure to highlight one recurrent 
deletion in exon 6. We found a previously unknown 6bp deletion in exon 6, downstream of the mutation 
cluster. This mutation would delete E307-P308 but is in frame with the rest of the protein.  This deletion 
was not observed in CAST/EiJ mouse sequencing.  It is unclear at this time if this is a CJ57BL/6 mutation 
or a specific mutation in the mouse sequenced.    
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Appendix E. TIN2 Knock-down and Overexpression Constructs and Methods 
 
Before using stable FLP-in cell lines and CRISPR/Cas9 genomic editing, we performed 
studies on TIN2 using the following lentiviral overexpression and shRNA knockdown 
techniques.  Protocols are listed here for future reference. 
 
Lentiviral Production and Transduction 
Lentivirus was produced for pGIPZ shRNA and pLenti6/UbC-TIN2-V5 constructs using 
a standard protocol.  To generate virus, 8x106 293FT cells were plated in a 15-cm plate 
coated with poly-D-Lysine (Sigma, P1024; 100μg/ml in water) in complete medium 
(DMEM, 10% FBS, 1% PSG).  The next day, the medium was changed to DMEM with 
1% FBS and no PSG. Cells were transfected with 9μg of the respective construct, 12 μg 
pCMVΔ8.91 (containing lentiviral gag and pol genes), and 3 μg pMD.G (containing 
lentiviral env gene) using Lipofectamine 2000 (Invitrogen, 11668) and Opti-MEM 
(Gibco) according to manufacturer protocol.  Cells were incubated at 37°C, 5% CO2 for 
72h. The cell medium was then harvested into a 50 mL conical tube, spun at 1000rpm to 
clear debris, and filtered through a 0.45μm filter prewetted with 1%FBS DMEM.  Virus 
was concentrated in Amicon Ultra-15 Centrifugal Filters by spinning at 4000xg in 5-
minute increments until the final volume is <0.5ml. Virus aliquots are stored at -80°C. 
pGIPZ lentivirus was titered by adding a series of dilutions of concentrated and 
unconcentrated virus to wells in a 24-well dish according to the pGIPZ manual.  48 hours 
post-transduction, cells were disrupted and inspected for GFP expression using flow 
cytometry. Viruses were transduced with an MOI of 0.3. 
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Suspension cells were transduced using a spinoculation protocol, where K562 
cells in media were spun at 800xg for 1 hour at 32°C with the appropriate amount of 




Lentiviral shRNA constructs were ordered from OpenBiosystems to target the TIN2 
3’UTR (pGIPZ V3LHS_395331; pGIPZ V3LHS_401958) and a non-targeting shRNA 
used as a control (pGIPZ RHS4346 D0709).  Expression constructs of the TIN2S and 
TIN2M isoforms are shRNA resistant because they have exogenous UTR sequence. 
Silent shRNA resistance mutations which were designed when cloning TIN2L, which 
contains some UTR sequence as coding sequence.  
 
Quantitative RT-PCR 
To measure relative amounts of TIN2 knock-down, RNA was isolated and reverse 
transcribed from TIN2 shRNA or scrambled shRNA cell lines. Quantitative RT-PCR was 
performed on a Bio-Rad CFX96 thermocycler. Approximately 5ng cDNA was mixed 
with 1X IQ SYBR Green Supermix (Bio-Rad, 1708884BUN) and 5 μM primers. TIN2 
primers are A32 and A33.  TIN2 expression levels were calculated relative to ARF3, 
which is measured with primers A21 and A22. Samples were measured in triplicate.  
Every plate contains a no template control for background and a no-RT control for DNA 
contamination.  
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Appendix F. Design for RCME at TINF2 locus 
We designed two approaches to cassette exchange at the endogenous TINF2 locus.  The 
first simply flanks the gene with heterologous loxP sites and selectable markers. The 
heterologous loxP sites make it possible to transfect an exogenous expression cassette 
with matching loxP sites for homologous recombination mediated by Cre recombinase 
(Toledo et al. 2006). The second approach was to add TIN2 cassettes downstream of the 
TINF2 gene as a lox-stop-lox cassette, where the endogenous gene could be removed and 
the downstream cassette could be simultaneously expressed. 
 
Appendix F.1. The first step of editing inserts the upstream loxP with a PuroΔTK gene which has a 
minimal sequence of puromycin resistance gene fused with thymidine kinase, so it can be used with both 
positive and negative selection.  The second step incorporates the heterologous LoxP site with a second 
selectable marker downstream of TINF2. Transfection with the recombination cassette and Cre recominase 
will replace the endogenous gene with the TIN2 construct of interest.  Counter selection with Ganciclovir 





Appendix F.2. The second approach to cassette exchange at the endogenous locus is to make the TINF2 
gene into a Lox-Stop-Lox cassette with a downstream TIN2 coding sequence that will be expressed after 
Cre-mediated removal of the endogenous cassette.  Endogenous and downstream cassettes are differentially 
epitope tagged for quality control of the Lox-Stop-Lox and for efficiency of Cre-mediated removal of the 
endogenous gene. Puro-delta-TK serves both positive selection for puromycin resistance and negative 
selection by thymidine kinase expression. 
 
These approaches can be used to ask specific questions that require removal of 
endogenous TIN2 expression, such as whether one specific TIN2 isoform is sufficient for 
telomere length maintenance, or if the TIN2 patient mutations have different effects 
depending on which isoform is expressed.  Because TIN2 knockout is lethal, this 
simultaneous exchange of endogenous for the expression construct of interest will be 
beneficial.  Technical challenges may arise, considering that the TIN2-DC mutation was 
lethal when homozygous (D Frescas & de Lange 2014), so both homozygous and 




Appendix G. Higher TERT expression in polycistronic expression cassette cannot 
be explained by polycistronic transcript context 
 
 
Appendix G. (A) We transfected TPP1 and POT1 plasmids to see if TPP1/POT1 stabilized telomerase 
expression. We observed a smear near the expected TERT molecular weight with TPP1 or TPP1/POT1 
transfection (arrow). This band shape not match TERT expression bands observed in TERT expression 
(lane next to arrow). Also shown are TPP1-2a-TERT and POT1-2a-TERT cell lines, generated to test 
dependence of TIN2 on TPP1/POT1.  (B) Transfection of TPP1 into hTR parent cell line with no FLAG-
TERT also produces the smeary band around TERT MW observed in A, so we conclude that this is a 
background band caused by TPP1 overexpression and not stabilization of TERT. (C) MG132 was added to 
the indicated cell lines (same cell lines as in A) for overnight at a1:1000 dilution (10mg/ml stock).  No 
appreciable difference between treatment was observed in the TERT cell lines. (D) MG132 treatment either 
6 or 24 hours where indicated. Concentrations were 0-200 μM. An increase in bands was apparent at 24 hr 
but they did not correspond to the expected TERT size ad were also found in the no MG132 lane. P53 blot 
(not shown) showed no difference. Results are inconclusive. (E) GFP-2A-TERT construct (F) Polycistronic 
transcript does not stabilize TERT, as TERT levels are still well below those in TPP1/POT1/TERT (see 
alsoTPP1/TERT and POT1/TERT in A, C) (G) GFP-2A-TERT has telomerase activity. Shown are assays 
with 2 or 6 μl lysate.  
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Appendix H. Reciprocal FLAG co-immunopreciptiation of TIN2 
 
Appendix H. FLAG immunoprecipitation pulls down myc-TIN2. Left, input samples. Right, IP samples. 




Appendix I. C-terminally tagged TIN2S, TIN2L do not stimulate telomerase 
 
Appendix I. No observed stimulation of telomerase processivity with C-terminally tagged TIN2 
constructs.  (A) Direct telomerase assays. TIN2S-V5 WT, K280E, and R282S or GW-lacZ-V5 control 
were transfected into TPP1/POT1/TERT cell lines.  Assays were stopped at 2.5, 5, or 10 minutes. A &B, 
duplicate transfections. (B) V5 western blots of lysates used in A.  (C) Direct telomerase assays of TIN2L-
V5 WT or K280E mutation, GW-lacZ-V5 and of mycTIN2-FL WT or K280E or GFP. Assays were 
stopped at 5 or 10 minutes. A&B, duplicate transfections  (D) V5 and myc western blots of lysates in C.  
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